A Case of Adrenocorticotropin-dependent Cushing Syndrome with Osilodrostat Exposure in Early Pregnancy

Posted on December 13, 2025 by MaryO

Abstract

Osilodrostat is a novel treatment for adrenocorticotropin-dependent Cushing syndrome; however, its safety during pregnancy has not been reported. This case involves a patient with Cushing disease who became pregnant while on osilodrostat. She was diagnosed at 31 years of age and underwent pituitary tumor removal. After a relapse at 35 years of age, she was initially treated with metyrapone but switched to osilodrostat and hydrocortisone because of nausea, achieving reasonable cortisol control. At 37 years of age, she unknowingly became pregnant despite irregular periods, and the pregnancy was detected at 16 weeks because of ongoing nausea. Osilodrostat was stopped, and she was started on pasireotide and metyrapone. The pregnancy proceeded normally despite elevated urinary free cortisol levels, although she contracted COVID-19 at 25 weeks. At 26 weeks and 1 day, preterm rupture of membranes and breech presentation led to an emergency cesarean section. The newborn had no adrenal insufficiency and developed normally. This case prompts consideration of whether osilodrostat can be used during pregnancy if risks are justified. Pasireotide is rarely used in pregnancy and may have limited effectiveness, but when given, can cause hyperglycemia because of insulin and incretin suppression and should be monitored carefully.

Introduction

Active Cushing syndrome decreases fertility, which explains its rarity in pregnancy. Fewer than 250 cases have been documented [1]. Whether it is ACTH-dependent or ACTH-independent, this disease poses significant risks to both mother and fetus. Its maternal complications include hypertension, preeclampsia, and diabetes [2], whereas the fetal risks include miscarriage, intrauterine growth restriction, and prematurity [3]. Given its rarity, there is no established standard of care for Cushing disease during pregnancy. Surgery offers a potential cure, but it can cause hypopituitarism and may not be feasible in the absence of a visible tumor [4]. Meanwhile, there are also risks associated with radiotherapy and pharmacological treatments [1, 4]. The use of pasireotide, a somatostatin analog, for the treatment of a GH-secreting pituitary macroadenoma without complications has been reported in only 1 case during pregnancy [5]. To the best of our knowledge, this drug has not been used for Cushing disease before. Osilodrostat, like metyrapone, is a newer steroidogenesis inhibitor that blocks 11β-hydroxylase in the adrenal glands. It is effective for both ACTH-dependent and ACTH-independent Cushing syndrome [6]. However, it is contraindicated in pregnancy because of its proven teratogenic effects in animal studies [7]. As a result, data on its use in human pregnancy are lacking. Understanding the normal physiology of the hypothalamic-pituitary-adrenal (HPA) axis in pregnancy is essential. In normal pregnancy, the maternal levels of corticotropin-releasing hormone, ACTH, and cortisol rise both in the serum and urine because of placental production [8, 9]. Although cortisol levels rise, only about 10% crosses the placenta because of 11β-hydroxysteroid dehydrogenase activity [10]. Fetal cortisol production remains minimal until late gestation, as 3β-hydroxysteroid dehydrogenase activity stays low until then [10]. Thus, most fetal cortisol originates from maternal sources [11]. In late pregnancy, fetal adrenal 3β-hydroxysteroid dehydrogenase activity increases, thereby enhancing fetal cortisol synthesis and promoting maturation of the HPA axis [10]. This case report discusses a female patient with recurrent Cushing disease who conceived while taking osilodrostat, which she took until early pregnancy; she was later treated successfully with pasireotide and metyrapone.

Case Presentation

A 30-year-old woman developed moon facies, central obesity, muscle weakness, and amenorrhea. Elevated levels of ACTH and cortisol, along with a roughly 6-mm pituitary adenoma, confirmed a diagnosis of Cushing disease. At 31 years of age, she successfully underwent transsphenoidal surgery, but 4 years later, biochemical relapse occurred with no identifiable residual tumor on imaging (Fig. 1). The patient was initially treated with metyrapone, but because of nausea, this was switched to osilodrostat. A block-and-replace approach was taken with osilodrostat 3 mg/day and hydrocortisone 10 mg/day, after which her cortisol levels normalized, but the menstrual irregularities persisted (Fig. 1).

 

Changes in urinary free cortisol (UFC) and pituitary magnetic resonance imaging (MRI) findings over time. The MRI scans at diagnosis, after surgery, at recurrence, and before pregnancy are shown alongside ACTH, cortisol, and UFC levels. The blood tests indicated recurrence, but no tumor was seen on MRI. Cortisol levels improved after osilodrostat treatment.

Figure 1.

Changes in urinary free cortisol (UFC) and pituitary magnetic resonance imaging (MRI) findings over time. The MRI scans at diagnosis, after surgery, at recurrence, and before pregnancy are shown alongside ACTH, cortisol, and UFC levels. The blood tests indicated recurrence, but no tumor was seen on MRI. Cortisol levels improved after osilodrostat treatment.

Diagnostic Assessment

At 38 years of age, the patient presented with nausea. The patient was followed up with an upper gastrointestinal endoscopy revealing no abnormalities. After a prolonged period of nausea, a pregnancy test revealed that she was 16 weeks pregnant.

Treatment

At this point, she had been on osilodrostat, which was immediately stopped and replaced with pasireotide 10 mg every 4 weeks because of pregnancy. Later, 24-hour urinary free cortisol (UFC) levels increased, leading to an early increase in pasireotide dose to 20 mg after 3 weeks before the recommended 4-week period elapsed; the same dose was administered every 4 weeks thereafter. And the same time, the initiation of up to 1000 mg metyrapone daily (Fig. 2). The patient also had hyperglycemia, which prompted insulin initiation, and subcutaneous heparin was also added because of the risk of thrombosis. At 25 weeks of pregnancy, she developed pharyngeal pain and a cough, which quickly resolved. At 26 weeks and 1 day, she experienced preterm premature rupture of membranes with the fetus in breech position, necessitating an emergency cesarean section. During this time, she tested positive for severe acute respiratory syndrome coronavirus 2 via polymerase chain reaction; however, she remained asymptomatic. Hydrocortisone was given before delivery as a steroid cover. Postpartum, osilodrostat was resumed, and pasireotide/metyrapone was discontinued. Two months after delivery, her disease remained stable, with UFC at 62.0 μg/day (171 nmol/day), within the normal reference range of 26.0 to 187.0 μg/day (72-516 nmol/day).

 

Urinary free cortisol (UFC) levels and medications during pregnancy. The UFC levels during pregnancy are shown. The UFC levels increased after stopping osilodrostat, and these remained high even after starting pasireotide. Adding metyrapone led to a decrease in the UFC.

Figure 2.

Urinary free cortisol (UFC) levels and medications during pregnancy. The UFC levels during pregnancy are shown. The UFC levels increased after stopping osilodrostat, and these remained high even after starting pasireotide. Adding metyrapone led to a decrease in the UFC.

Outcome and Follow-up

A live baby girl was born with extremely low birth weight, weighing 871 g. She was admitted to the neonatal intensive care unit with Apgar scores of 2 and 10 at 1 and 5 minutes, respectively, and was temporarily placed on a ventilator because of respiratory distress syndrome. During her stay, no signs of adrenal insufficiency appeared, and blood samples taken at noon showed ACTH levels of 23.3 pg/mL (5.1 pmol/L) and cortisol levels of 2.7 µg/dL (74.5 nmol/L). The normal reference ranges in adults are 7.2 to 63.3 pg/mL (1.6-13.9 pmol/L) for ACTH and 4.5 to 21.1 µg/dL (124.2-582.1 pmol/L) for cortisol. She was discharged at 40 weeks’ corrected gestational age, with subsequent normal growth and development.

Discussion

It remains challenging to manage Cushing disease during pregnancy because of limited treatment options and fetal safety concerns. An important aspect of managing hypercortisolemia in pregnancy is understanding the physiological regulation of the maternal-fetal HPA axis. In infants with very low birth weight, cortisol levels measured within an hour after birth typically range from 3.6 to 10.8 µg/dL (99-298 nmol/L) [12]. Although the neonate in this case had lower cortisol levels (2.7 µg/dL, 74.5 nmol/L), the blood sample was taken around noon, a time when levels are usually lower. Nevertheless, no signs of adrenal insufficiency were observed. Because newborns develop a stable cortisol rhythm within the first month [13], these findings suggest adequate adrenal function. Better obstetric outcomes can be expected when maternal hypercortisolism is successfully managed, such as reduced rates of prematurity and low birth weight [14]. A previous case report noted successful delivery after treatment with metyrapone, targeting UFC levels below 150 µg/day (414 nmol/day) [15]. Metyrapone was necessary in this patient because the cortisol levels were rising despite pasireotide monotherapy. This was gradually titrated to control UFC levels, which achieved some success. We introduced pasireotide during pregnancy based on previous reports of its use in acromegaly without adverse fetal outcomes [5]. However, pasireotide carries significant risk of hyperglycemia because of its inhibitory effects on insulin and incretin secretion [16]; this was seen in our patient, who required insulin therapy. Although rarely used in pregnancy—with only 1 reported case to our knowledge—it may be considered a viable option if other treatments are unsuccessful or unsuitable. Osilodrostat is contraindicated during pregnancy because it has shown teratogenic effects in animal studies, leading to limited human data [6]. In this case, the patient was unknowingly exposed during early pregnancy. However, no fetal malformations were observed, and this could be attributed to the underdeveloped fetal adrenal cortex during early gestation, which mainly relies on maternal hormone supply [10]. Osilodrostat was resumed after delivery, achieving effective disease control and clinical stability. It is also essential to consider that the preterm birth in this case may have resulted from suboptimal cortisol control, maternal COVID-19 infection, and the use of osilodrostat and pasireotide—drugs with minimal clinical data for use during pregnancy. These factors cannot be excluded entirely. However, based on our expertise, the contraindication of osilodrostat in pregnancy may warrant reevaluation.

Learning Points

  • Osilodrostat should not be used during pregnancy. Although preterm birth in this case may have resulted from various factors—including limited clinical data on osilodrostat and pasireotide—that the neonate showed no congenital abnormalities or adrenal problems indicates that the current caution against using osilodrostat in pregnancy might need to be reconsidered.
  • In early pregnancy, the fetal adrenal glands are immature and dependent on maternal hormones, so the effects of drugs that inhibit adrenal steroid synthesis may be relatively minor.
  • Pasireotide is rarely used during pregnancy. If administered, close monitoring is necessary, as insulin and incretin suppression may induce hyperglycemia.

From https://academic.oup.com/jcemcr/article/3/12/luaf269/8327956?login=false

 

Filed under: Cushing's, pituitary, Treatments | Tagged: , , , , , | Leave a comment »

Predictors of Cancer in Patients With Endogenous Cushing’s Syndrome

Posted on July 21, 2025 by MaryO

We previously reported an increase in overall cancer risk in patients with endogenous Cushing’s syndrome (CS), mainly during the 10-year period following CS diagnosis.

To identify predictors of cancer in patients with CS, we conducted this retrospective nationwide cohort study of patients with CS, diagnosed between 2000 and 2023 in Israel. The cohort comprised 609 patients with CS (age at diagnosis, 48.1 ± 17.2 years; 65.0% women) and 3,018 age-, sex-, socioeconomic status-, and body mass index-matched controls (1:5 ratio).

Patients were grouped according to the occurrence of any malignancy within 10-years after the diagnosis of CS. Cox proportional hazards models, with death as a competing event, were used to identify predictors of cancer development. Independent predictors of cancer development in patients with CS included age ≥60 years (HR 1.75, 95% CI 1.01–2.68), male gender (HR 1.67, 95% CI 1.04–3.05), and adrenal-origin CS (HR 1.66, 95% CI 1.01–2.73). Baseline urinary-free cortisol levels were not associated with cancer development. Patients with ≥4 CS-associated comorbidities had a higher cancer risk (HR 1.76, 95% CI 1.03–3.02; age- and sex-adjusted). The overall 10-year risk of malignancy was twice as high in patients with CS compared to matched controls, with cancer developing, on average, 5 years earlier in patients with CS (62.3 ± 15.0 vs 67.2 ± 12.3 years). Cancer-related mortality at 10-years was twice as high in deceased patients with CS, compared to deceased controls. In conclusion, age ≥60 years at CS diagnosis, male gender, and adrenal-origin CS are independent predictors of cancer diagnosis within 10-years of initial confirmation of CS.

 

Introduction

Prolonged cortisol exposure may promote cancer development and growth (Mayayo-Peralta et al. 2021, Khadka et al. 2023). Epidemiological research showed that extended glucocorticoids use is associated with elevated overall cancer risk (Oh & Song 2020). Recently, several studies suggested that cortisol levels increase cancer risk in patients with endogenous Cushing’s syndrome (CS). A Danish study found higher rates of cancer at the time of CS diagnosis compared to controls (Dekkers et al. 2013). A Swedish study examined comorbidity rates in patients with CS and identified a nonsignificant trend of increased cancer rates in CS compared to the general population, but was probably underpowered for this relatively rare outcome (Papakokkinou et al. 2020). Our nationwide retrospective matched-cohort study, using the Clalit Health Services (CHS) database in Israel (including 609 patients with CS and 3,018 age-, sex-, socioeconomic status- and body mass index (BMI)-matched controls), observed higher rates of all cancer types in patients with CS, with a hazard ratio (HR) of 1.78 (95% CI 1.44–2.20) (Rudman et al. 2024). Elevated cancer incidence was evident in patients with Cushing’s disease (CD) and in patients with adrenal CS. The overall cancer risk remained elevated during the first 10 years that followed CS diagnosis (Rudman et al. 2024). Similarly, a nationwide cohort study from Taiwan investigated the association between endogenous CS and cancer incidence, and reported a standardized incidence ration of 2.08 (95% CI 1.54–2.75) for cancer in patients with endogenous CS (Wu et al. 2025).
Hypercortisolemia and CS-associated comorbidities could drive malignancy development in patients with CS (Rudman et al. 2024, Wu et al. 2025). While it is known that the incidence of diabetes, obesity and insulin resistance is higher in patients with CS than that of the general population (Pivonello et al. 2016, Fleseriu et al. 2021, Reincke & Fleseriu 2023) – all of which are linked to cancer development (Renehan et al. 2008, Ling et al. 2020) – it remains unclear whether these comorbidities specifically contribute to the risk of malignancy within the CS population.
Thus, the aims of the present study were to identify the baseline predictors of cancer development in CS and to test the hypothesis that cumulative cortisol exposure, measured by urinary-free cortisol (UFC), predicts cancer risk in patients with CS.

Methods

Study design and data collection

We conducted a retrospective matched-cohort study using the electronic health record database of Clalit Health Services (CHS), the largest health maintenance organization (HMO) in Israel with over 4.8 million members. The CHS database includes demographic and clinical data, hospital and outpatient clinic diagnoses, medication dispensation, and all laboratory test results conducted at the HMO’s laboratories. All diagnoses and respective dates were identified using the International Classification of Diseases, tenth revision (ICD-10) codes (Supplementary Table S1 (see section on Supplementary materials given at the end of the article)). Weight and height data, and smoking status, were recorded regularly during visits to primary care clinics and in some specialized clinics. 24 h UFC results were collected and the normal reference range for each kit used. As these tests were performed by several different laboratories and devices (in all cases the bioanalytical method used was an immunoassay test), the results were reported as multiples of the upper limit of normal (×ULN). Data were extracted using the CHS research data-sharing platform, powered by MDClone. Importantly, the diagnoses of chronic medical conditions, recorded at the time of CS diagnosis, were validated: any member of CHS who required chronic treatment for a medical condition (e.g., medication for hypertension or diabetes) could only receive his prescriptions if the primary physician has registered the diagnosis, coded according to the ICD-10, in the computerized system. Mortality data were collected from the hospital’s mortality database, which is updated from the Ministry of Interior’s population registry. Data on cancer-specific mortality were obtained from hospital discharge certificates at the time of the hospitalization that ultimately resulted in the patient’s death. The study protocol, including detailed data collection methods, has been previously published (Rudman et al. 2024).

Ethical approval

The study was approved by the institutional ethics review board of Rabin Medical Center. As data were collected anonymously and in a retrospective manner, a waiver of informed consent was granted.

Patients and outcome measures

The methods we used for patient selection and matched controls selection have been previously published (Rudman et al. 2024), as the current study is based on the same group of patients with CS and controls. After the initial screening, potential cases with ICD-10 diagnosis of CS had to fulfill at least one of the following criteria: i) 24 h UFC ≥4 ×ULN, ii) 24 h UFC ≥3 ×ULN and surgical intervention to remove a pituitary or adrenal adenoma, and iii) 24 h UFC ≥2 ×ULN and metyrapone, ketoconazole, osilodrostat, cabergoline, or pasireotide treatment. All patients with CS and non-suppressed adrenocorticotropic hormone (ACTH) levels who did not receive pituitary-directed therapy and were diagnosed with a malignancy possibly causative of ectopic CS, including small-cell lung carcinoma, bronchial and thymic carcinoids, medullary thyroid carcinoma, neuroendocrine tumors or pheochromocytoma, were suspected of ectopic CS and were excluded from this study (Rudman et al. 2024). Patients diagnosed with adrenocortical carcinoma before or within 5 years of CS diagnosis were excluded.
All identified cases were individually matched in a 1:5 ratio with age-, sex-, socioeconomic status-, and BMI-matched controls from the general population (CHS members who have never been tested for suspected hypercortisolism). The age of the individually matched controls matched the age of cases ±12 months.
The follow-up period began at the time of CS diagnosis for all cases (newly diagnosed patients with CS) and at the exact same day for each individually matched control. It continued until death, termination of CHS membership, or until the date of data collection (June 30, 2023).
The main outcome measure was the first diagnosis of any malignancy following CS diagnosis, excluding non-melanoma skin cancer. Recurrences of known malignancies were also excluded.

Statistical analysis

The statistical analysis was generated using the SAS Software, Version 9.4, SAS Institute Inc., Cary, NC, USA. Continuous variables were presented by the mean ± standard deviation or median (interquartile range (IQR)). Categorical variables were presented by (n, %). Normality of continuous variables was assessed using the Kolmogorov–Smirnov test. The t-test, Mann–Whitney test, and chi-square test were used for comparison of normally distributed, non-normal, and categorical variables, respectively. The Cox proportional hazard model, with death without malignancy treated as a competing risk, was used to calculate both univariate and multivariate HR; the Fine and Gray methodology for dealing with competing risks was used, both in the cumulative incidence plots and in HR calculations. Baseline variables found to be associated with malignancy in the univariate analysis (with a between-group P-value below 0.05) were incorporated into the multivariate model. The appropriateness of the proportional hazard assumption was assessed visually. Two-sided P-values less than 0.05 were considered statistically significant.

Results

Patient characteristics

From January 1, 2000, to June 30, 2023, a total of 609 patients with CS met the study inclusion criteria (65.0% women, mean age at CS diagnosis of 48.1 ± 17.2 years). All cases of CS were matched with up to five controls based on age, sex, socioeconomic status, and BMI, and amounted to a total of 3,018 controls. Baseline characteristics of all 609 patients and 3,018 controls, with subdivisions according to disease source, are shown in Table 1.

Table 1. Baseline characteristics (at diagnosis/time 0) of patients with Cushing’s syndrome (CS) and matched control of all patients with CS, Cushing’s disease (CD), and adrenal CS.

Baseline characteristics, all patients with CS CS (n = 609) Matched controls (n = 3,018) P value CD (n = 251) Matched controls (n = 1,246) P value Adrenal CS (n = 200) Matched controls (n = 991) P value
Age, years, mean (SD) 48.1 (17.2) 47.9 (17.2) 45.7 (17.8) 45.7 (17.8) 51.1 (16.6) 51.0 (16.6)
Sex, no. (%)
 Females 396 (65.0) 1,975 (65.4) 164 (65.3) 818 (65.6) 137 (68.5) 684 (69.0)
 Males 213 (35.0) 1,043 (34.6) 87 (34.7) 428 (34.4) 63 (31.5) 307 (31.0)
Socioeconomic status, no. (%)a
 Low 74 (12.8) 371 (13.0) 34 (14.2) 172 (14.5) 20 (10.5) 99 (10.4)
 Middle 349 (60.6) 1,719 (60.3) 145 (60.7) 713 (60.2) 119 (62.6) 594 (62.9)
 High 153 (26.6) 760 (26.7) 60 (25.1) 300 (25.3) 51 (26.9) 252 (26.7)
Body mass index, Kg/m2, mean (SD)b 30.9 (7.6) 30.0 (6.9) 30.2 (7.4) 29.6 (6.8) 30.8 (7.1) 30.3 (6.3)
Source of hypercortisolism, no. (%)
 Cushing’s disease 251 (41.2)
 Adrenal Cushing’s syndrome 200 (32.8)
 Indeterminatec 158 (25.9)
Smoking status, no. (%)d 0.35 0.77 0.18
 Non-smoker 198 (59.8) 910 (62.6) 87 (64.0) 387 (65.3) 61 (53.0) 327 (60.1)
 Smoker/former smoker 133 (40.2) 544 (37.4) 49 (36.0) 206 (34.7) 54 (47.0) 217 (39.9)
Comorbidities, no. (%)
 Diabetes mellitus 140 (23.0) 396 (13.1) <0.01 55 (21.9) 148 (11.9) <0.01 51 (25.5) 158 (15.9) <0.01
 Hypertension 343 (56.3) 957 (31.7) <0.01 129 (51.4) 338 (27.1) <0.01 129 (64.5) 387 (39.0) <0.01
 Dyslipidemia 258 (42.4) 874 (29.0) <0.01 97 (38.6) 305 (24.5) <0.01 97 (48.5) 339 (34.2) <0.01
 Ischemic heart disease 70 (11.5) 191 (6.3) <0.01 23 (9.2) 67 (5.4) 0.03 25 (12.5) 77 (7.8) 0.04
 Cerebrovascular disease 27 (4.4) 82 (2.7) 0.04 12 (4.8) 35 (2.8) 0.11 10 (5.0) 32 (3.2) 0.21
 Osteoporosis 75 (12.3) 187 (6.2) <0.01 26 (10.4) 57 (4.6) <0.01 28 (14.0) 82 (8.3) 0.02
 Malignancy before CS diagnosis 50 (8.2) 117 (3.9) <0.01 15 (6.0) 48 (3.9) 0.12 20 (10.0) 50 (5.0) 0.01
Cases and controls were individually matched for age, sex, socioeconomic status, and body mass index.
a
Cushing’s syndrome n = 576, controls n = 2,850; Cushing’s disease n = 239, controls n = 1,185; adrenal Cushing’s syndrome n = 190, controls n = 945.
b
Cushing’s syndrome n = 363, controls n = 1,549; Cushing’s disease n = 152, controls n = 644; adrenal Cushing’s syndrome n = 131, controls n = 570.
c
Ectopic ACTH secretion and adrenocortical carcinoma were excluded.
d
Cushing’s syndrome n = 331, controls n = 1,454; Cushing’s disease n = 136, controls n = 593; adrenal Cushing’s syndrome n = 115, controls n = 544.
At baseline, diabetes mellitus, hypertension, dyslipidemia, ischemic heart disease, and osteoporosis were more common among patients with CS (P < 0.01). Smoking rates were similar between the two groups (Table 1). A prior history of malignancy was more prevalent among patients with CS than controls (8.2 vs 3.9%, respectively; P < 0.01) (Table 1).

Predictors of new malignancy in patients with Cushing’s syndrome

Table 2 presents the baseline characteristics of 609 patients with CS, including demographic data, CS etiology, history of malignancy before CS diagnosis, maximal UFC at diagnosis, and CS-associated comorbidities. In a univariate time-to-event analysis of the 10-year cumulative cancer risk, accounting for death as a competing event, we found that age ≥60 years at CS diagnosis, male gender, adrenal-origin CS, hypertension, dyslipidemia, and ischemic heart disease at baseline were all associated with a higher cancer risk. The 10-year cumulative cancer risk, with death as a competing event, stratified by age, sex, and CS etiology is shown in Fig. 1. Prior malignancy, diabetes, and obesity were not associated with an increased risk of malignancy in patients with CS (Table 2). The cohort was divided into three groups based on baseline UFC level (below 5 ×ULN, 5–10 ×ULN, and above 10 ×ULN) with comparison of time to cancer occurrence. Higher UFC levels at the time of CS diagnosis were not associated with cancer development (Table 2 and Fig. 2). In a multivariable Cox regression model (multivariable model 1, Table 2), we found that age ≥60 years at CS diagnosis (HR 1.75, 95% CI 1.01–2.68), male gender (HR 1.67, 95% CI 1.04–3.05), and adrenal-origin CS (HR 1.66, 95% CI 1.01–2.73) were independent predictors of cancer development within 10 years after CS diagnosis. In an additional model (multivariable model 2, Table 2), we observed that patients with ≥4 CS-associated comorbidities at the time of CS diagnosis had a higher risk of cancer (HR 1.76, 95% CI 1.03–3.02), after adjustment for age and sex.

Table 2. Univariate analysis and multivariable regression models for the 10-year cumulative cancer risk in patients with Cushing’s syndrome, accounting for death as a competing event.

Baseline characteristics Patients (n = 609) Incident cases of cancer (n = 81) Deaths without cancer (n = 40) Univariate analysis Multivariable model 1* Multivariable model 2 (total no. of CS-associated comorbidities, with age and sex adjustment)
Age <60 years (ref) 444 44 10 – – –
Age ≥60 years 165 37 30 2.47 (1.60–3.82) 1.75 (1.01–2.68) 3.18 (2.09–4.86)
Female (ref) 396 42 23 – – –
Male 213 39 17 1.75 (1.13–2.70) 1.67 (1.04–3.05) 1.60 (1.11–2.29)
Low SESa 74 13 5 1.29 (0.65–2.56)
Medium SESa 349 42 21 0.87 (0.52–1.45)
High SES (ref)a 153 22 13 –
Cushing’s disease (ref)b 251 27 21 – –
Adrenal CSb 200 39 8 1.87 (1.14–3.05) 1.66 (1.01–2.73)
Non-smoker (ref)c 198 25 12 –
Smoker/former smokerc 133 21 12 1.25 (0.70–2.23)
Prior malignancy 50 6 14 0.91 (0.40–2.08)
No prior malignancy (ref) 559 75 26 –
Maximal urinary free cortisold
 <5 × ULN (ref) 231 38 18 –
 5–10 × ULN 135 18 7 0.86 (0.49–1.48)
 ≥10 × ULN 70 10 4 0.89 (0.45–1.78)
CS-associated comorbidities
 Obesitye 176 28 17 1.22 (0.71–2.11)
 No obesity (ref)e 187 24 12 –
 Diabetes mellitus 140 21 14 1.28 (0.78–2.10)
 No diabetes mellitus (ref) 469 60 26 –
 Hypertension 343 59 34 2.23 (1.36–3.65) 1.52 (0.83–2.81)
 No hypertension (ref) 266 22 6 – –
 Dyslipidemia 258 44 29 1.81 (1.17–2.81) 0.97 (0.55–1.72)
 No dyslipidemia (ref) 351 37 11 – –
 Ischemic heart disease 70 19 11 2.70 (1.62–4.51) 1.48 (0.81–2.71)
 No ischemic heart disease (ref) 539 62 29 –
 Stroke 27 3 2 1.07 (0.33–3.49)
 No stroke (ref) 582 78 38 –
 Osteoporosis 75 9 9 0.92 (0.46–1.84)
 No osteoporosis (ref) 534 72 31 –
Total no. of CS-associated comorbiditiesf
 0–1 (ref) 295 27 9 – –
 2–3 205 33 15 2.09 (1.36–3.22) 1.40 (0.87–2.26)
 ≥4 109 21 16 3.76 (2.37–5.97) 1.76 (1.03–3.02)
CS, Cushing’s syndrome; SES, socioeconomic status; ULN, upper limit of normal. Bold indicates statistical significance.
*
Included variables: age, sex, source of hypercortisolism, hypertension, dyslipidemia, and ischemic heart disease.
a
n = 576.
b
Ectopic ACTH secretion and adrenocortical carcinoma were excluded.
c
n = 331.
d
Maximal value of urinary-free cortisol divided by the upper limit of normal of the specific assay, n = 436.
e
n = 363.
f
CS-associated comorbidities include obesity, diabetes mellitus, hypertension, dyslipidemia, ischemic heart disease, and osteoporosis.
Figure 1

  1. Download: Download high-res image (201KB)
  2. Download: Download full-size image

Figure 1. The 10-year cumulative cancer risk, with death as a competing event, among patients with Cushing’s syndrome, according to age at diagnosis (A), sex (B), and Cushing’s syndrome etiology (C). CD, Cushing’s disease; CS, Cushing’s syndrome. A full colour version of this figure is available at https://doi.org/10.1530/ERC-25-0059.

Figure 2

  1. Download: Download high-res image (61KB)
  2. Download: Download full-size image

Figure 2. The 10-year cumulative cancer risk, with death as a competing event, among patients with Cushing’s syndrome, according to the maximal value of UFC divided by the upper limit of normal (ULN) of the specific assay used: UFC <5 × ULN (reference), 5–10 × ULN, and ≥10 × ULN. A full colour version of this figure is available at https://doi.org/10.1530/ERC-25-0059.

Univariate analysis and multivariable regression models for the 10-year cumulative cancer risk in patients with CD and adrenal CS are presented in Tables 3 and 4. In the univariate time-to-event analysis of 251 patients with CD, age ≥60 years at CS diagnosis and the presence of dyslipidemia and ischemic heart disease at baseline were associated with higher cancer risk. The multivariable Cox regression model did not identify any significant predicting factors in patients with CD. Tables 3 and 4 also present the univariate analysis for the 10-year cumulative cancer risk in 200 patients with adrenal CS, which showed that age ≥60 years, male gender, and ischemic heart disease were associated with cancer development. In the multivariable model, only age ≥60 years at CS diagnosis (HR 2.66, 95% CI 1.36–5.18) was found to be independently associated with cancer development in patients with adrenal CS (Table 4). UFC levels at the time of CS diagnosis were not associated with new cancer diagnosis in either patients with CD or with adrenal CS (Tables 3 and 4).

Table 3. Univariate analysis and multivariable regression models for the 10-year cumulative cancer risk in patients with Cushing’s disease, accounting for death as a competing event.

Cushing’s disease baseline characteristics Patients (n = 251) Incident cases of cancer (n = 27) Deaths without cancer (n = 21) Univariable Multivariable model 1 Multivariable model 2 (total no. of CS-associated comorbidities, with age and sex adjustment)
Age <60 years (ref) 196 16 8 – – –
Age ≥60 years 55 11 13 2.72 (1.27–5.81) 1.83 (0.65–5.18) 3.54 (1.81–6.92)
Female (ref) 164 14 14 – – –
Male 87 13 7 1.79 (0.85–3.80) 1.61 (0.73–3.56) 1.22 (0.68–2.18)
Low SESa 34 5 5 1.29 (0.42–3.99)
Medium SESa 145 13 12 0.81 (0.32–2.00)
High SES (ref)a 60 7 4 –
Non-smoker (ref)b 87 6 6 –
Smoker/former smokerb 49 8 8 2.59 (0.91–7.39)
Prior malignancy 15 26 15 0.66 (0.09–5.13)
No prior malignancy (ref) 236 1 6 –
Maximal urinary-free cortisolc
 <5 × ULN (ref) 133 15 14 –
 5–10 × ULN 70 6 3 0.78 (0.31–2.00)
 ≥10 × ULN 40 6 4 1.48 (0.57–3.79)
CS-associated comorbidities
 Obesityd 69 7 10 0.80 (0.31–2.09)
 No obesity (ref)d 83 10 6 –
 Diabetes mellitus 55 5 6 0.89 (0.34–2.35)
 No diabetes mellitus (ref) 196 22 15 –
 Hypertension 129 17 17 1.67 (0.76–3.64)
 No hypertension (ref) 122 10 4 –
 Dyslipidemia 97 15 13 2.31 (1.08–4.96) 1.64 (0.58–4.61)
 No dyslipidemia (ref) 154 12 8 – –
 Ischemic heart disease 23 5 4 2.71 (1.03–7.08) 1.29 (0.43–3.86)
 No ischemic heart disease (ref) 228 22 17 – –
 Stroke 12 2 1 2.34 (0.53–10.30)
 No stroke (ref) 239 25 20 –
 Osteoporosis 26 24 15 1.14 (0.35–3.66)
 No osteoporosis (ref) 225 3 6 –
Total no. of CS-associated comorbiditiese
 0–1 (ref) 136 11 6 – –
 2–3 74 10 8 2.19 (1.13–4.26) 1.48 (0.72–3.04)
 ≥4 41 6 7 3.69 (1.78–7.66) 1.72 (0.73–4.02)
CS, Cushing’s syndrome; SES, socioeconomic status; ULN, upper limit of normal. Bold indicates statistical significance.
a
n = 239.
b
n = 136.
c
Maximal value of urinary free cortisol divided by the upper limit of normal of the specific assay; n = 243.
d
Cushing’s disease, n = 152.
e
CS-associated comorbidities include obesity, diabetes mellitus, hypertension, dyslipidemia, ischemic heart disease, and osteoporosis.

Table 4. Univariate analysis and multivariable regression models for the 10-year cumulative cancer risk in patients with adrenal Cushing’s syndrome, accounting for death as a competing event.

Adrenal Cushing’s syndrome baseline characteristics Patients with CS at risk (n = 200) Incident cases of cancer (n = 39) Deaths without cancer (n = 8) Univariable Multivariable model 1 Multivariable model 2 (total no. of CS-associated comorbidities, with age and sex adjustment)
Age <60 years (ref) 134 20 1 – – –
Age ≥60 years 66 19 7 2.12 (1.13–3.96) 2.66 (1.36–5.18) 2.70 (1.35–5.42)
Female (ref) 137 17 3 – – –
Male 63 22 5 2.97 (1.58–5.58) 1.81 (0.94–3.51) 3.11 (1.73–5.57)
Low SESa 20 3 0 0.62 (0.17–2.28)
Medium SESa 119 22 3 0.73 (0.36–1.44)
High SES (ref)a 51 13 5 –
Non-smoker (ref)b 61 12 3 –
Smoker/former smokerb 54 10 2 0.86 (0.38–1.99)
Prior malignancy 20 4 2 1.03 (0.38–2.81)
No prior malignancy (ref) 180 35 6 –
Maximal urinary free cortisolc
 <5 × ULN (ref) 98 23 4 –
 5–10 × ULN 65 12 4 0.84 (0.42–1.69)
 ≥10 × ULN 30 4 0 0.53 (0.18–1.52)
CS-associated comorbidities
 Obesityd 64 15 4 1.68 (0.75–3.74)
 No obesity (ref)d 67 10 3 –
 Diabetes mellitus 51 12 3 1.47 (0.75–2.89)
 No diabetes mellitus (ref) 149 27 5 –
 Hypertension 129 29 7 1.73 (0.84–3.58)
 No hypertension (ref) 71 10 1 –
 Dyslipidemia 97 20 7 1.20 (0.65–2.25)
 No dyslipidemia (ref) 103 19 1 –
 Ischemic heart disease 25 10 4 2.65 (1.31–5.34) 1.51 (0.68–3.32)
 No ischemic heart disease (ref) 175 29 4 – –
 Stroke 10 1 1 0.58 (0.08–4.35)
 No stroke (ref) 190 38 7 –
 Osteoporosis 28 2 2 0.32 (0.08–1.33)
 No osteoporosis (ref) 172 37 6 –
Total no. of CS-associated comorbiditiese
 0–1 (ref) 82 14 1 – –
 2–3 76 15 2 1.24 (0.62–2.48) 0.95 (0.44–2.02)
 ≥4 42 10 5 2.46 (1.20–5.05) 1.21 (0.51–2.85)
CS, Cushing’s syndrome; SES, socioeconomic status; ULN, upper limit of normal. Bold indicates statistical significance.
a
n = 190.
b
n = 115.
c
Maximal value of urinary-free cortisol divided by the upper limit of normal of the specific assay; n = 193.
d
n = 131.
e
CS-associated comorbidities include obesity, diabetes mellitus, hypertension, dyslipidemia, ischemic heart disease, and osteoporosis.

The 10-year cancer risk in patients with Cushing’s syndrome vs controls

In the 10 years following CS diagnosis, 81 (13.3%) patients with CS were diagnosed with cancer and 40 (6.6%) died without malignancy, compared with 206 (6.8%) and 152 (5.0%) controls, respectively. Similar to the previously reported risk for the entire follow-up period (Rudman et al. 2024), the overall 10-year risk of malignancy, calculated with death as a competing event, was twice as high in patients with CS than in matched controls (HR 2.01; 95% CI, 1.55–2.60) (Supplementary Fig. S1).
The mean age of cancer development in patients with CS was 62.3 ± 15.0 years, compared with 67.2 ± 12.3 years in controls (P < 0.01). The risk of cancer across different subgroups (patients with CS vs controls) is shown in Fig. 3 and Table 5. The number of cases for each type of cancer in patients with CS and controls is shown in Supplementary Table S2.
Figure 3

  1. Download: Download high-res image (222KB)
  2. Download: Download full-size image

Figure 3. The 10-year cancer risk in subgroups of the entire cohort (cases vs matched controls). Cases and controls were individually matched for age, sex, socioeconomic status, and body mass index.

Table 5. The 10-year cancer risk in subgroups of the entire cohort (cases vs matched controls).

Subgroup Cushing’s syndrome Individually matched controls HR 95% CI
Patients Incident cases of cancer Deaths Patients Incident cases of cancer Deaths
Age
 <60 444 44 10 2,200 84 30 2.67 1.85–3.85
 ≥60 165 37 30 818 122 122 1.55 1.08–2.24
Sex
 Females 396 42 23 1,975 117 89 1.83 1.29–2.61
 Males 213 39 17 1,043 89 63 2.25 1.54–3.28
Socioeconomic status
 Low 74 13 5 371 14 17 5.03 2.37–10.68
 Middle 349 42 21 1,719 116 90 1.83 1.28–2.60
 High 153 22 13 760 73 36 1.52 0.94–2.45
Smoking status
 Smoker/former smoker 133 21 12 544 46 34 1.84 1.09–3.10
 Non-smoker 198 25 12 910 66 48 1.79 1.13–2.83
Comorbidities
 Obesity 176 28 17 698 45 62 2.52 1.57–4.04
 No obesity 187 24 12 851 70 46 1.58 0.99–2.51
 Diabetes mellitus 140 21 14 396 45 75 1.35 0.80–2.25
 No diabetes mellitus 469 60 26 2,622 161 77 2.13 1.58–2.86
 Hypertension 343 59 34 957 106 126 1.59 1.16–2.19
 No hypertension 266 22 6 2,061 100 26 1.71 1.07–2.72
 Dyslipidemia 258 44 29 874 100 100 1.53 1.07–2.17
 No dyslipidemia 351 37 11 2,144 106 52 2.15 1.47–3.13
 Ischemic heart disease 70 19 11 191 30 49 1.89 1.06–3.35
 No ischemic heart disease 539 62 29 2,827 176 103 1.88 1.41–2.52
 Stroke 27 3 2 82 7 17 1.50 0.39–5.74
 No stroke 582 78 38 2,936 199 135 2.02 1.56–2.63
 Osteoporosis 75 9 9 187 23 32 0.98 0.45–2.10
 No osteoporosis 534 72 31 2,831 183 120 2.15 1.64–2.83
Cases and controls were individually matched for age, sex, socioeconomic status, and body mass index.
Among 487 cases and 2,411 controls with an attainable follow-up period of at least 10 years, 52 patients with CS and 184 controls died (from any cause) during the 10 years that followed CS diagnosis. Eight (15.4%) patients with CS died due to malignancy, compared with 12 (6.5%) patients in the control group (P = 0.04).
During the 10-year follow-up after CS diagnosis, 27 out of 251 patients with CD (10.8%) were diagnosed with malignancy, compared to 71 (5.7%) controls. Among 200 patients with adrenal CS, 39 (19.5%) were diagnosed with cancer, compared to 79 (8.0%) controls. The 10-year risk of overall malignancy was higher in patients with CD (HR 1.92, 95% CI 1.23–3.00) and in patients with adrenal CS (HR 2.63, 95% CI 1.79–3.87), compared to controls (Supplementary Fig. S1). The number of cases for each specific cancer type in patients with CD and adrenal CS and their individually matched controls is elaborated in Supplementary Table S2.

Sensitivity analyses

Due to possible bias in individuals with a genetic predisposition to cancer, and in patients at increased risk due to prior cancer treatment, we excluded all patients with prior history of cancer (50 cases and 117 controls). Following this exclusion, patients with CS still exhibited a higher 10-year cancer risk (HR 2.12, 95% CI 1.62–2.77).
Patients with adrenal cancer diagnosed before or within 5 years of CS diagnosis were excluded from the study. However, as it is possible that adrenal cancer was either not recorded properly or unrecognized at the time of CS diagnosis, we performed an analysis of the risk of malignancy excluding all adrenal cancer cases and found no change in the 10-year risk of overall cancer (HR 1.92, 95% CI 1.48–2.50).
The diagnosis of CS patients in the study included an ICD-10 coding of the diagnosis and laboratory evidence of hypercortisolism (and test date) in all cases. However, because in many cases the diagnostic and treatment process are lengthy, there is a possibility of information bias caused by patients included in the database who were diagnosed before the time period included in the study. Therefore, we performed a sensitivity analysis excluding the first year of the study, without any change in the 10-year risk of malignancy among CS patients (HR 1.98, 95% CI 1.51–2.58).

Discussion

Patients with CS have higher morbidity and mortality (Gadelha et al. 2023, Loughrey et al. 2024), and it has been recently established that CS is associated with an increased cancer risk (Rudman et al. 2024, Wu et al. 2025). However, predictors of a new cancer diagnosis have not been studied. In this nationwide retrospective study, the 10-year cancer risk in 609 patients with CS was twice as high as in 3,018 matched controls. Importantly, the 10-year risk was notably higher in patients with CD (HR 1.92, 95% CI 1.23–3.00) and in those with adrenal CS (HR 2.63, 95% CI 1.79–3.87), compared to controls. Furthermore, the risk of cancer was higher in patients with CS, regardless of age and sex. On average, cancer development in patients with CS occurred at an age that was 5 years younger than that of controls who developed cancer (62.3 ± 15.0 vs 67.2 ± 12.3 years, respectively).
Our study is the first to identify predictors of new cancer diagnosis in patients with CS. A multivariate regression model showed that age ≥60 years at CS diagnosis (HR 1.75, 95% CI 1.01–2.68), male gender (HR 1.67, 95% CI 1.04–3.05), and adrenal-origin CS (HR 1.66, 95% CI 1.01–2.73) were identified as independent predictors of cancer development within 10 years. In addition, we found that patients with ≥4 CS-associated comorbidities at the time of CS diagnosis had an increased risk of cancer (HR 1.76, 95% CI 1.03–3.02; adjusted for age and sex). Interestingly, diabetes and obesity were not associated with malignancy development in patients with CS. Importantly, we found no association between UFC levels at the time of CS diagnosis and cancer development rates.
CS most commonly affects young women, a population not inherently at high risk for malignancy, with the exception of breast cancer (National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program, December 2024. https://seer.cancer.gov/statfacts/html/aya.html). Our study demonstrates that young patients and female patients with CS are at an increased risk of cancer, as compared with matched controls from the general population. However, within the group of patients with CS, we found age and sex disparities in malignancy risk: men and elderly patients (over 60 years of age) showed a higher cancer risk (Table 2). Advanced age is a universal risk factor for cancer (Campisi 2013), and patients with CS are no exception. Previous studies found that male patients with CS are more susceptible to metabolic derangements than female patients (Liu et al. 2015, Broersen et al. 2019), a difference that likely results from gender disparity in response to glucocorticoid receptor activation (Bourke et al. 2012).
In addition, our study found that CS of adrenal origin is associated with a higher risk of malignancy, as compared with CD, after adjustment for age, sex, and significant CS-related comorbidities. Notably, patients with a history of adrenal cancer or ectopic CS were excluded. This finding is difficult to explain, since most studies have found that patients with CD present with higher UFC levels (Berr et al. 2015, Rubinstein et al. 2019, Schernthaner-Reiter et al. 2019) and a longer delay in diagnosis (Rubinstein et al. 2019, Schernthaner-Reiter et al. 2019) compared to those with adrenal CS. One potential explanation for this observation is that adrenal adenomas may be linked to a higher incidence of malignancy, as studies have shown that cancer mortality is increased with autonomic cortisol secretion, with malignancy being the most common cause of death in patients with mild autonomous cortisol secretion (Patrova et al. 2017, Deutschbein et al. 2022). Another conceivable explanation stems from previous research that reported higher rates of non-adrenal malignancies in patients with bilateral adrenal tumors and autonomous cortisol secretion (Kawate et al. 2014), suggesting a possible genetic predisposition in patients with adrenal adenoma that may contribute to the development of overall cancer.
Interestingly, in our study, patients with adrenal CS had a history of malignancy at a higher rate than their individually matched controls at the time of CS diagnosis (Table 1). In contrast, no difference in the rate of malignancy was found between patients with CD and controls. Although it is possible that a prior history of malignancy contributed to the higher risk of cancer observed in patients with adrenal CS, we did not find that a prior malignancy predicted subsequent cancer risk in this population when we analyzed our cohort of patients with adrenal CS (Table 4).
In this study, we found no association between the cumulative exposure to excess glucocorticoids (measured as UFC levels) and the development of malignancy (Fig. 2), but we did identify an association between the total number of CS-related comorbidities and cancer risk (adjusted for age and sex) (Table 2). Previous studies have similarly shown no correlation between the degree of hypercortisolism and the presence of CS-related comorbidities in patients with CS (Schernthaner-Reiter et al. 2019), including diabetes and obesity (Giordano et al. 2014, Bavaresco et al. 2024). Those findings support the hypothesis that individual sensitivity to glucocorticoids varies across tissues, such that UFC levels do not always correlate with symptom burden or comorbidities. Patients who are more sensitive to excess cortisol may experience a broader range of CS-associated comorbidities. Several genetic mutations and alterations have already been identified as causes of variation in cortisol sensitivity, including the genes encoding the human glucocorticoid receptor (NR3C1) (Chrousos et al. 1982, Riebold et al. 2015, Laulhé et al. 2024), the chaperone protein that regulates proper folding of the glucocorticoid receptor (HSP90) (Riebold et al. 2015), and the nuclear protein that modulates glucocorticoid receptor actions (NR2C2) (Zhang et al. 2016). In addition, mutations in glucocorticoid response elements (Vandevyver et al. 2013), variations in RNA-binding to the glucocorticoid receptor (Lammer et al. 2023), and epigenetic changes (Paes et al. 2024) may also play a role in inter-individual differences in response to cortisol excess.
In the univariate model we have performed, the total number of CS-related comorbidities was associated with cancer development, and the risk of malignancy increased with the number of comorbidities. However, after adjustment for age and sex, the HR was significantly moderated (mainly due to a strong correlation between age and comorbidity) but remained graded. We find this observation to support the concept that cancer is a CS-associated comorbidity, and suggest that patients with CS (especially older men with adrenal CS) suffering from multiple disease-related comorbidities require closer follow-up and a rigorous age-adjusted cancer screening, in accordance with guidelines for the general population.
We have previously reported an increased risk of genitourinary, thyroid, and gynecological cancers in patients with CS (Rudman et al. 2024). A Taiwanese national cohort study reported that liver (27.7%), kidney (16.7%), and lung (13.0%) cancers were the most common cancers among patients with CS (Wu et al. 2025). Despite the small absolute number of cases in each cancer type in this study, we found that the incidence in patients with CS was higher across all cancer groups, except for malignant melanoma. One might think that patients with CS underwent more imaging and laboratory tests, and therefore more cases of low-risk cancers (e.g., clinically insignificant prostate or thyroid cancer) were diagnosed in patients with CS than in controls. However, as we have shown, the overall 10-year malignancy-associated mortality was twice as high in patients with CS compared to controls, indicating that malignancies in this group were clinically significant.
Surgery for CS, especially for CD, improves some but not all comorbidities (Dekkers et al. 2013, Terzolo et al. 2014, Papakokkinou et al. 2020, Puglisi et al. 2024). Improvement of comorbidities with medical therapy have been noted in several clinical trials (Fleseriu et al. 2012, 2022, Petersenn et al. 2017); however, there are no prospectively collected data on the risk of cancer in these patients treated long-term. A retrospective study examining the course of several CS-related comorbidities showed that the risk of cancer in patients with CS who did not achieve remission was higher compared to the risk of cancer for patients in remission, yet these analyses did not reach statistical significance, partly due to the limited sample size (Papakokkinou et al. 2020).
In order to successfully identify predictors of cancer in patients with CS, this research of an uncommon outcome (malignancy) in patients with a rare disease (CS) required a long-term follow-up of a large, population-representative cohort, paired with well-matched control group. Matching for socioeconomic status is another strength of this study, as its impact on morbidity has recently been demonstrated in several studies (Ebbehoj et al. 2022, Claudel & Verma 2024).
However, this study has limitations. Missing data prevented us from determining the specific CS etiology in some patients. Correct classification of all cases with an indeterminate diagnosis (as either CD or adrenal CS) would have allowed us to improve the power of subgroup analysis of patients with CD and adrenal CS; however, we had very strict criteria for determining the etiology of CS. Not all data regarding socioeconomic status, BMI, and smoking status were available. In addition, the impact of hypopituitarism and overreplacement of glucocorticoids in patients with CD could not be assessed.
Since the control group was drawn from the general population, ascertainment bias cannot be ruled out, as it is likely that patients with CS underwent more physician-initiated imaging and laboratory tests, and therefore more cases of cancer could have been diagnosed in patients with CS than in controls. However, we consider this bias to be unlikely for most cases of aggressive cancer, especially given our long follow-up period.
While this nationwide study includes a relatively large sample size, we acknowledge that it is likely that our current sample size was not sufficiently powered to detect risk predictors that are only modestly associated with malignancy risk. The small sample size of subgroups and the low frequency of the outcome in these subgroups meant we were unable to predict malignancy in patients with CD or adrenal CS, nor could we estimate the risk of specific malignancies. Moreover, we could not account for certain factors that may influence the risk of malignancy, such as family history of malignancy, duration of exposure to elevated cortisol levels, and the presence of genetic syndromes that predispose individuals to both CS and certain malignancies (e.g., multiple endocrine neoplasia type 1) (Hernández-Ramírez & Stratakis 2018). Finally, the lack of systematic prospective assessment of comorbidities is an important limitation and should raise the standards for future clinical care of these patients and collecting data in new registries. While patients receiving treatment for a particular comorbidity were successfully identified, those without treatment were not systemically recorded, which may have led to underreporting. Such is the case with osteoporosis: only patients who received treatment or whose treating physician decided to send them for a bone density scan were diagnosed, while others without such evaluations were assumed to be free of osteoporosis.
In conclusion, this large nationwide retrospective matched-cohort study found that the risk of cancer was consistently higher in patients with CS, regardless of age or sex, and on average, cancer development occurred 5 years earlier in patients with CS than in controls. The multivariate regression model we developed identified age ≥60 years at CS diagnosis, male gender, and CS of adrenal-origin as independent predictors of malignancy during the 10 years following CS diagnosis. Importantly, we found no association between UFC levels at CS diagnosis and cancer development rates. However, patients with ≥4 CS-associated comorbidities at CS diagnosis were more likely to develop cancer, after adjusting for age and sex. Given previous studies that identified overall cancer as a CS-related comorbidity and as one of the leading causes of death in this population, the results of the current study will help identify patients at high risk of malignancy, emphasize the importance of timely screening tests, in accordance with guidelines for the general population, and highlight the need for larger international cohorts to establish specific cancer screening recommendations for patients with CS.

Supplementary materials

This is linked to the online version of the paper at https://doi.org/10.1530/ERC-25-0059.

Declaration of interest

Yaron Rudman, Genady Drozdinsky, Hiba Masr-Iraqi, Tzippy Shochat, and Shiri Kushnir do not have any financial or personal relationships with other people or organizations to disclose. Maria Fleseriu has been a PI with research funding to the university from Crinetics and Sparrow and has received occasional scientific fees for scientific consulting and advisory boards from Crinetics, Recordati, Sparrow and Xeris. Ilan Shimon has been an investigator for Xeris Biopharma and has received occasional scientific fees for scientific consulting and advisory boards from Medison, CTS pharma, and Neopharm. Amit Akirov has received occasional scientific fees for scientific consulting and advisory boards from Medison, CTS pharma, and Neopharm.

Funding

This work did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Data availability

The data that support the findings of this study are available from Clalit Health Services. Restrictions apply to the availability of these data, which were used under license for this study. Deidentified individual participant-level data sharing will be considered by the corresponding author of this study, with the permission of Clalit Health Services. All applicants will be asked to sign a data access agreement. All requests will be assessed as to whether data sharing is appropriate, based on the scientific rigor of the proposal.

References

Filed under: Cancer, Clinical trials, Cushing's, Treatments | Tagged: , , , , , , | Leave a comment »

A Prospective Trial With Ketoconazole Induction Therapy and Octreotide Maintenance Treatment for Cushing’s Disease

Posted on June 21, 2025 by MaryO

Abstract

Context and Objective

The lack of efficacy of somatostatin receptor subtype 2 (SST2) preferring somatostatin analogs in patients with Cushing’s disease (CD) results from a downregulating effect of hypercortisolism on SST2 expression. Our objective is to evaluate the efficacy of a strategy with sequential treatment of ketoconazole to reduce cortisol levels and potentially restore SST2 expression followed by octreotide as maintenance therapy in patients with CD.

Patients and Design

Fourteen adult patients with CD were prospectively enrolled. Patients started with ketoconazole. Once cortisol levels were normalized, octreotide was initiated. After 2 months of combination therapy, patients were maintained on octreotide monotherapy until the end of the study period (9 months). Treatment success was defined by normalization of urinary free cortisol (UFC) levels.

Results

Ketoconazole was able to normalize UFC levels in 11 (79%) patients. Octreotide effectively sustained normal levels of UFC in 3 patients (27%) (responders). Four patients (36%) showed a partial response. The remaining 4 (36%) patients developed hypercortisolism as soon as ketoconazole was stopped (nonresponders). Octreotide responders had lower UFC levels at baseline when compared to partial responders and nonresponders (1.40 ± 0.07 vs 2.05 ± 0.20 UNL, P = 0.083). SST2 mRNA was highly expressed in adenomas of 2 responder patients (0.803 and 0.216 copies per hprt).

Conclusion

Sequential treatment with ketoconazole to lower cortisol levels followed by octreotide to maintain biochemical remission according to UFC may be effective in a subset of patients with mild CD, suggesting that cortisol-mediated suppression of SST2 expression is a reversible process.

Transsphenoidal adenomectomy is the first-line treatment of Cushing’s disease (CD) [1-3]. Medical therapy can be used as an adjunctive preoperative treatment or in persistent or recurrent disease [2, 4, 5]. Pharmacological treatment of CD can be divided into 3 approaches: pituitary-directed therapy, steroids synthesis inhibitors, and glucocorticoid receptor antagonists [4]. Because of limited efficacy and side effects, a combination of drugs is often necessary to achieve biochemical control [2, 5-8].

Steroid synthesis inhibitors are often used as a first-line medical treatment modality. Ketoconazole and metyrapone can normalize cortisol production in about 50% to 60% of patients, whereas the recently introduced steroidogenic enzyme inhibitor osilodrostat has an efficacy of up to 80% [9-11]. Pharmacotherapy targeting the corticotroph tumor itself may be a more rational approach since it exerts effects at the cause of the disease [2, 5, 12]. The most commonly used drugs in this category are cabergoline, a dopamine agonist, and pasireotide, a second-generation somatostatin analog [2, 3, 13]. Cabergoline inhibits ACTH secretion through agonism of the dopamine type 2 receptor, expressed in the majority of corticotroph tumors [14, 15]. However, cabergoline is able to normalize the cortisol secretion in less than half the patients, and a substantial number of patients escape from treatment [4, 8, 16, 17]. Several small studies show promising effects of cabergoline combined with ketoconazole [7, 8]. Pasireotide exhibits high-affinity binding to somatostatin receptor subtype (SST) 5, which is the SST expressed at the highest level in corticotroph pituitary adenomas. Pasireotide shows moderate efficacy in normalizing cortisol levels in a subset of patients with mild to moderate hypercortisolism, with hyperglycemia as an important side effect [13, 18, 19].

Octreotide, a somatostatin analog with high binding affinity to SST2, was shown to lower ACTH production in patients with corticotroph tumor progression following bilateral adrenalectomy but was unsuccessful in patients with active CD [20, 21]. Table 1 provides an overview of the clinical studies using octreotide in CD. Tumoral pituitary corticotroph cells express about 5 to 10 times higher SST5 compared to SST2, which may explain the reduced efficacy of octreotide compared to pasireotide in inhibiting ACTH secretion in primary cultures of human corticotroph tumors as well as in vivo [13, 28]. This is explained by selective suppressive effects of high cortisol concentrations in active CD on SST2 expression, resulting in an absent treatment response to octreotide [13, 29, 30]. Hence, it may be hypothesized that normalizing or lowering cortisol levels in patients with CD can result in a reciprocal increase in SST2 expression by corticotroph tumor cells. Under such conditions, the use of octreotide could play a potential role in CD management based on its safer toxicity profile compared to pasireotide [31].

 
Table 1.

Literature review: octreotide treatment in patients with Cushing’s disease

Study n Maximal octreotide dose Response criteria Full response Partial response No response Maximal treatment duration
Invitti et al, 1990 [22] 3 1200 µg/day UFC 1 2 49 days
Lamberts et al, 1989 [20] 3 100 µg (single injection) Serum cortisol 3 Trial 12 hours
Arregger et al, 2012 [21] 2 Oct-lar (20 mg/month) UFC 2 4 months
Woodhouse et al, 1993 [23] 4 100-500 µg (every 8 hours) Serum cortisol 4 Trial 24-72 hours
El-Shafie et al, 2015 [24] 6 100 µg (every 8 hours) Serum cortisol 6 Trial 72 hours
Ambrosi et al, 1990 [25] 4 100 µg (single injection) Serum cortisol 4 Trial 7 hours (CRH stimulus)
Stalla et al, 1994 [26] 5 100 µg (30 and 180 minutes) serum cortisol 5 Trial 400 minutes (CRH stimulus)
Vignati et al, 1996 [27] 3 100 µg (single injection)/300 µg/day Serum cortisol/UFC 1 2 Trial 8 hours/75 days
Total 30 0 2 (7%) 28

Abbreviation: Oct-lar, long acting repeatable octreotide; UFC, urinary free cortisol.

We previously demonstrated that in corticotroph adenomas obtained from CD patients who were in biochemical remission before surgery, induced by medical treatment, SST2 mRNA expression was significantly higher compared to corticotroph tumor tissue from patients with hypercortisolism at the time of operation [32]. In fact, SST2 mRNA levels in adenomas from these normocortisolemic patients were comparable to those of GH-producing adenomas, which are usually responsive to SST2-preferring somatostatin analogs [32]. In this pilot study, we, therefore, aim to evaluate the clinical efficacy of a sequential regimen with ketoconazole induction therapy to reduce cortisol levels in CD and potentially restore SST2 expression at the level of the corticotroph adenoma, followed by octreotide treatment to reduce ACTH secretion.

Methods

Study Population

Adult patients with recently diagnosed treatment-naïve CD or with persistent or recurrent hypercortisolism after transsphenoidal surgery were eligible for enrollment. Patients already on medical treatment for CD were included only after a drug washout period of 4 weeks and following confirmation of hypercortisolism. Exclusion criteria included elevated liver enzymes, renal insufficiency, history of pituitary radiotherapy, symptomatic cholelithiasis, and pregnancy.

The study protocol was approved by the ethical committees of the participating centers. All patients gave their written informed consent. The trial was registered by the Dutch Trial Register (nr. NL37105.078.11).

Diagnostic Workup of CD

Upon clinical evidence of CD, the diagnosis was biochemically established by elevated 24-h urinary free cortisol (UFC) concentrations (3 samples), failure in suppressing plasma cortisol after 1 mg of dexamethasone, and increased midnight saliva cortisol levels. ACTH dependency was defined on the basis of normal to high ACTH plasma levels. Additionally, plasma cortisol diurnal rhythm was assessed with measurement at 9 Am, 5 Pm, 10 Pm, and midnight. Once a diagnosis of ACTH-dependent hypercortisolism was confirmed, magnetic resonance imaging was performed to detect a pituitary tumor. In the absence of a lesion, or a lesion of less than 6 mm, bilateral inferior petrosal sinus sampling was performed to confirm central ACTH overproduction.

Drug Regimen Protocol

After inclusion, patients were followed monthly for up to 9 months. All patients started with ketoconazole; the initial dose depended on the severity of hypercortisolism, with 600 mg per day for mild hypercortisolism [UFC ≤ 1.5 times the upper limit of normal (ULN)] and 800 mg per day for a higher level of hypercortisolism (UFC >1.5 times the ULN). (Fig. 1). If necessary, the dose of ketoconazole could be uptitrated to 1200 mg per day after 2 months to achieve biochemical remission according to UFC excretion. Once UFC levels were normalized, long acting repeatable (LAR) octreotide treatment was initiated at a dose of 20 mg every 4 weeks. If UFC concentrations remained normal after 2 months of combined therapy (ketoconazole plus octreotide), ketoconazole was discontinued and patients were maintained on octreotide monotherapy until the end of the study period. If the UFC level (mean of 2 samples) was increased above the ULN, the octreotide dose was increased from 20 to 30 mg every 4 weeks. This may have occurred earlier, while octreotide was still combined with ketoconazole, or later, on octreotide monotherapy.

 

Study protocol. If UFC excretion (mean of 2 collections) increases again (above the ULN) under octreotide/ketoconazole combination therapy or octreotide monotherapy (20 mg every 4 weeks), the octreotide dosage will be increased to 30 mg every 4 weeks.

Figure 1.

Study protocol. If UFC excretion (mean of 2 collections) increases again (above the ULN) under octreotide/ketoconazole combination therapy or octreotide monotherapy (20 mg every 4 weeks), the octreotide dosage will be increased to 30 mg every 4 weeks.

Abbreviations: CAB, cabergoline; UFC, urinary free cortisol.; ULN, upper limit of normal.

Response to octreotide was defined as the maintenance of normal UFC levels after ketoconazole discontinuation until the end of the study period, while partial response was defined as normal UFC levels maintained for at least 1 month after ketoconazole discontinuation and/or a >50% decrease of UFC levels at the last follow-up visit compared to the baseline value. Lack of response to octreotide was defined by the inability of octreotide to maintain normal UFC levels after discontinuation of ketoconazole. In this respect, a persistently elevated UFC concentration for 2 consecutive months was considered as treatment failure, after which the study protocol was terminated earlier, before the study period of 9 months. In case of biochemical remission, octreotide monotherapy was maintained until the end of the study period of 9 months, after which octreotide could be continued or replaced by another treatment modality.

In case ketoconazole therapy for 3 months failed to control cortisol production, a different treatment regimen was introduced. Cabergoline instead of octreotide was added to ketoconazole in an attempt to achieve biochemical control. Cabergoline, starting at 0.5 mg every other day, was gradually increased up to 1 and eventually 2 mg every other day, as needed, and ketoconazole was gradually reduced from 1200 to 400 mg per day within 4 weeks. If successful, this combination treatment (ketoconazole and cabergoline) was maintained until the end of the study period.

Side-effects Monitoring

Between the visits, patients were contacted by telephone for monitoring of adverse events. At each visit, laboratory evaluation was performed of pituitary function, hematology, blood chemistry, liver enzymes and renal function, hemoglobin A1c, glucose, and insulin levels.

During treatment with ketoconazole, concentrations of liver enzymes (aspartate transaminase, alanine transaminase, alkaline phosphatase, and gamma glutamyl transferase) were regularly measured. In case of an increase in liver enzymes (>4x ULN), the ketoconazole dose was decreased by 50%. If dose reduction did not lead to normalization of liver enzyme concentrations, ketoconazole was stopped with termination of the study. If relative adrenal insufficiency developed with steroid withdrawal complaints, the cortisol-lowering medication was stopped and eventually restarted at a lower dose. In case of absolute adrenal insufficiency hydrocortisone replacement therapy was started in addition to interruption of study medication. Electrocardiography was performed at baseline and at follow-up visits.

Assessment of Treatment Efficacy

Twenty-four-hour urinary cortisol excretion (2 collections) was measured at each monthly visit. Plasma cortisol diurnal rhythm (CDR) was assessed at baseline and at 3, 6, and 9 months. Recovery of CDR was defined by a serum cortisol concentration at midnight of less than 67% of that at 0900 hours (Pm/am ratio >0.67) [33]. Biochemical remission was defined as normalization of UFC concentrations, ie, the mean of 2 collections below the ULN.

Assessment of Clinical Parameters

Physical examination including measurement of blood pressure, heart rate, weight, height, body mass index, and waist circumference was performed at baseline and assessed monthly. Additionally, a routine laboratory examination, including full blood count, electrolytes, creatinine, blood urea nitrogen, liver enzymes, lipase, amylase, bilirubin, glucose, insulin, and glycosylated hemoglobin, was conducted at each visit.

Quantitative PCR

Eleven patients underwent surgery after the study period. In 4 patients, sufficient corticotroph pituitary adenoma tissue was available to assess SST2 mRNA expression. To assess the purity of the samples, GH mRNA relative to pro-opiomelanocortin (POMC) mRNA was calculated. Only samples with a GH/POMC ratio less than 10% for normal pituitary tissue were used in this analysis [34].

Quantitative PCR was performed following a protocol as previously described [35]. Briefly, poly A+ mRNA was isolated from corticotroph adenoma cells using oligo (dT)25 dynabeads (Invitrogen, Breda, The Netherlands). Subsequently, 23 µL H2O was added for elution, and 10 µL of poly A mRNA was used to synthesize cDNA using a commercial RevertAid First Strand cDNA synthesis kit (Thermo Scientific, Breda, The Netherlands). The assay for RT-qPCR was performed using Taqman Universal PCR mastermix (Applied Biosystems, Breda, The Netherlands) supplemented with sst2 forward and reverse primers and probes. (Supplementary Table S1) [36]. The expression of SST2 mRNA was determined relative to the hypoxanthine phosphoribosyltransferase (HPRT) housekeeping gene.

Immunohistochemistry

From 4 patients, representative adenoma tissue was available for immunohistochemistry (IHC). IHC was performed on 4-µm thick whole slide sections from formalin-fixed paraffin-embedded tissue blocks, on a validated and accredited automated slide stainer (Benchmark ULTRA System, VENTANA Medical Systems, Tucson, AZ, USA) according to the manufacturer’s instructions. Briefly, following deparaffinization and heat-induced antigen retrieval, the tissue samples were incubated with rabbit anti-SST2A antibody (Biotrend; NB-49-015-1ML, dilution 1:25) for 32 minutes at 37°C, followed by Optiview detection (#760-500 and #760-700, Ventana). Counterstain was done by hematoxylin II for 12 minutes and a blue coloring reagent for 8 minutes. Each tissue slide contained a fragment of formalin-fixed paraffin-embedded pancreatic tissue as an on-slide positive control. A semiquantitative immunoreactivity scoring system (IRS) was used by 2 independent investigators to assess SST2 immunostaining. IRS is based on 2 scales: first, the fraction of positive-stained cells > 80%, 51% to 80%, 10% to 50%, <10% and 0 and second, the intensity of immunostaining as strong, moderate, weak, and negative. The product of these 2 factors was used to calculate the IRS final score (range from 0 to 12) [37].

Statistical Analysis

Given the proof-of-concept nature of the present study, no formal statistical power and sample size calculations were performed. Patients were grouped according to the level of response to treatment in responders, partial responders, and nonresponders. For statistical comparisons, partial responders and nonresponders were grouped together and compared to responders.

Continuous variables are expressed as mean ± SEM. Categorical variables are expressed as counts and percentages. For comparisons between groups, Student’s t-test was used. For paired comparisons (baseline vs follow-up), paired t-test was used. Statistical significance was set at P < .05. GraphPad Prism version 5.01 was used for statistical analysis.

Results

Study Population

Sixteen patients with CD were prospectively enrolled, of whom 14 started the study protocol. One patient withdrew at baseline, and 1 patient was excluded because of pseudo-Cushing’s syndrome due to a psychiatric disorder. The mean age was 48.6 years; 64% (n = 9) were female; 86% (n = 12) were newly diagnosed and naïve in treatment; and 71% (n = 10) presented with mild hypercortisolism, defined as a UFC level <2 times the ULN, at baseline. The average treatment duration in this study was 6 months. Hypertension was the most common comorbidity (93%), followed by diabetes mellitus (50%) and dyslipidemia (43%). The majority of patients (79%, n = 11) exhibited a flattened cortisol rhythm with persistently high levels of plasma cortisol throughout the day (Table 2).

 
Table 2.

Baseline demographic and clinical characteristics of the study population

Characteristics Population (n = 14)
Female sex, no. (%) 9 (64.28)
Age at study, mean (median), years 48.64 (48)
Status of CD, no. (%)
 Newly diagnosed 12 (86)
 Persistent 1 (7.1)
 Recurrent 1 (7.1)
UFC level, times ULN, mean (median) 1.84 (1.76)
ACTH, mean, pg/mL 10.23 ± 6.8
Severity of CD, no. (%)a
 Mild 10 (71.42)
 Moderate 4 (28.57)
 Severe 0 (0)
Disturbed circadian diurnal rhythm, no. (%)b 11 (78.6)
Months of study completed, mean (median) 6.43 (7)
MRI, no. (%)
 Nonvisible adenomas 3 (21)
 Microadenomas 9 (64)
 Macroadenomas 2 (14)
Comorbidities, no. (%)
 Diabetes 7 (50)
 Hypertension 13 (92.85)
 Heart/vascular disease 3 (21.42)
 Dyslipidemia 6 (42.85)
 Obesity 5 (35.71)

Abbreviations: CD, Cushing’s disease; MRI, magnetic resonance imaging; UFC, urinary free cortisol; ULN, upper limit of normal.

aMild hypercortisolism was defined as UFC level less than 2 times the ULN, moderate hypercortisolism as UFC level between 2 and 5 times the ULN, and severe hypercortisolism as UFC level above 5 times the ULN.

bDisturbed circadian diurnal rhythm was defined as serum cortisol concentration at 2400 hours/serum cortisol concentration at 0900 hours (Pm/am ratio) above 0.67 [33].

Ketoconazole Treatment

All patients started treatment with ketoconazole monotherapy at a dose of 600 to 800 mg per day depending on baseline UFC level. In 11 patients (79%), normal values of UFC were achieved after 1 or 2 months of treatment. One patient developed symptoms of hypocortisolism with nausea, vomiting, and dizziness. Ketoconazole was discontinued and restarted a week later with a lower dose (200 mg/day), also resulting in normal UFC levels. Another patient discontinued the treatment in the first week because of clinical intolerance. A transient increase in liver enzymes was observed in 5 patients (39%), but no patient had to stop the study protocol because of liver toxicity. Most patients who achieved normal values of UFC (n = 11 out of 14; 79%) lost weight (mean weight loss = 7 ± 4.6 kg) during ketoconazole treatment. No abnormalities were found on electrocardiography during treatment with ketoconazole and octreotide mono- or combination therapy.

According to the study protocol, octreotide (20 mg every 28 days) was added to ketoconazole in the 11 patients who achieved normal cortisoluria. With the combination treatment, 9 patients (82%) sustained normal UFC levels. In 2 patients with recurrent hypercortisolism, increasing the dose of octreotide from 20 to 30 mg/4 weeks normalized UFC levels. Ketoconazole treatment was then stopped, and all patients continued octreotide (20 or 30 mg per month) monotherapy.

Octreotide Treatment

Octreotide monotherapy maintained normal levels of UFC in 3 patients (27%) (responders, Fig 2A). Four (36%) other patients showed a partial response to octreotide (Fig. 2B shows the responses in the individual patients). In 3 of these patients, normal UFC levels were sustained for 1 or 2 months following discontinuation of ketoconazole, and in the other partial responder, the UFC levels at the last follow-up visit had decreased by 57% compared to the baseline levels. The remaining 4 patients developed hypercortisolism as soon as ketoconazole was stopped (nonresponders, Fig. 2C). Responders to octreotide monotherapy had lower UFC levels at baseline when compared to partial responders and nonresponders, with a trend to statistical significance (P = .083) (Table 3). No differences were observed between the 2 groups (responders vs partial responders and nonresponders) related to age, sex, number of comorbidities, and baseline and follow-up cortisol diurnal rhythm (Table 3).

 

Levels of UFC under sequential KTC and Octr treatment. (A) Octr responders (n = 3, patients 7, 8, 13). All patients started treatment with KTC monotherapy at a dose of 600 mg per day. Subsequently, Octr (20 mg every 28 days) was added to the treatment regimen. After 2 months of combined therapy, KTC was discontinued. In 2 cases, this led to a gradual increase in UFC levels requiring a higher dose of Octr (30 mg/month). All 3 patients then remained in remission under Octr monotherapy. (B) Octr partial responders (n = 4, patients 5, 10, 14, and 16). The patients followed different treatment schedules. Patient 5 started with KTC monotherapy followed by 1 month of combined treatment (KTC + Octr) and subsequent Octr monotherapy. Under Octr treatment, the patient was in remission for 2 months. Patient 10 started with KTC monotherapy, followed by 3 months of combined treatment (KTC + Octr) because of an escape of the treatment requiring an increase in the dose of Octr from 20 to 30 mg/month and subsequently went on Octr 30 mg/month monotherapy. Under Octr treatment, the patient was in remission for 2 months. Patient 14 started with KTC monotherapy, achieving remission of the disease in the second month, followed by 2 months of combined treatment (KTC + Octr) and subsequent Octr monotherapy. Under Octr treatment, the patient was in remission for 1 month. The last patient (no. 16) started with KTC monotherapy, achieving a normal cortisol level, followed by combined treatment and subsequent Octr monotherapy. UFC levels at follow-up had decreased by 57% compared to baseline. (C) Octr nonresponders (n = 4, patients 2, 4, 12, and 15). All patients started treatment with KTC monotherapy at a dose of 600 to 800 mg per day. Subsequently, Octr was added to the treatment for 2 months. KTC was discontinued in the third month, which led to a gradual increase in UFC levels. Despite the increased dose of Octr (30 mg/month), all patients failed to maintain disease remission. Data represent mean ± SEM.

Figure 2.

Levels of UFC under sequential KTC and Octr treatment. (A) Octr responders (n = 3, patients 7, 8, 13). All patients started treatment with KTC monotherapy at a dose of 600 mg per day. Subsequently, Octr (20 mg every 28 days) was added to the treatment regimen. After 2 months of combined therapy, KTC was discontinued. In 2 cases, this led to a gradual increase in UFC levels requiring a higher dose of Octr (30 mg/month). All 3 patients then remained in remission under Octr monotherapy. (B) Octr partial responders (n = 4, patients 5, 10, 14, and 16). The patients followed different treatment schedules. Patient 5 started with KTC monotherapy followed by 1 month of combined treatment (KTC + Octr) and subsequent Octr monotherapy. Under Octr treatment, the patient was in remission for 2 months. Patient 10 started with KTC monotherapy, followed by 3 months of combined treatment (KTC + Octr) because of an escape of the treatment requiring an increase in the dose of Octr from 20 to 30 mg/month and subsequently went on Octr 30 mg/month monotherapy. Under Octr treatment, the patient was in remission for 2 months. Patient 14 started with KTC monotherapy, achieving remission of the disease in the second month, followed by 2 months of combined treatment (KTC + Octr) and subsequent Octr monotherapy. Under Octr treatment, the patient was in remission for 1 month. The last patient (no. 16) started with KTC monotherapy, achieving a normal cortisol level, followed by combined treatment and subsequent Octr monotherapy. UFC levels at follow-up had decreased by 57% compared to baseline. (C) Octr nonresponders (n = 4, patients 2, 4, 12, and 15). All patients started treatment with KTC monotherapy at a dose of 600 to 800 mg per day. Subsequently, Octr was added to the treatment for 2 months. KTC was discontinued in the third month, which led to a gradual increase in UFC levels. Despite the increased dose of Octr (30 mg/month), all patients failed to maintain disease remission. Data represent mean ± SEM.

Abbreviations: KTC, ketoconazole; Octr, octreotide; UFC, urinary free cortisol (24 hours).

 
Table 3.

Clinical characteristics of responder compared to partial/nonresponder patients

Characteristics Responders Partial/nonresponders P-value
No. of patients 3 8
Age (years) (mean ± SEM) 39.67 ± 6.88 52 ± 4.30 .163
Number of comborbidities (mean ± SEM) 2.33 ± 0.33 2.38 ± 0.57 .967
Initial UFC (mean ± SEM) 1.40 ± 0.07 2.05 ± 0.20 .083
Baseline CDR, Pm/am ratio (mean ± SEM) 0.85 ± 0.14 0.91 ± 0.10 .752
Follow-up CDR, Pm/am ratio (mean ± SEM) 0.61 ± 0.17 0.81 ± 0.11 .43

Abbreviations: CDR, circadian diurnal rhythm; UFC, urinary free cortisol.

Responders

Individual patient numbers in brackets refer to the patient numbers in Figs. 2 and 3 and Supplementary Table S1 [36]. In 2 (patients 8 and 13) of the 3 responders, UFC levels gradually increased after discontinuation of ketoconazole treatment, requiring an increase in the octreotide dose from 20 to 30 mg that ultimately induced sustained normalization of UFC levels (Fig. 2A). Overall, among responders, the mean UFC levels at baseline was 1.40 ± 0.07 times the ULN and 0.62 ± 0.19 times the ULN at follow-up at the end of the study period (P = .09). Regarding the CDR, 2 patients (no. 7 and 13) at baseline exhibited disturbed CDR, and in 1 patient (no. 8), it was slightly altered. Full recovery of the CDR at follow-up was observed in 2 patients (no. 7 and 8), including the 1 (no. 8) with discrete alteration, while in another (patient 13), there was a partial recovery. On average, patients exhibited a numerically lower cortisol Pm/am ratio at follow-up as compared to baseline (baseline Pm/am ratios 0.86 ± 0.14 and 0.62 ± 0.09 at follow-up, P = .15). In terms of clinical features of CD, 2 (no. 7 and 13) of the 3 patients showed improvement in weight, waist circumference, and systolic and diastolic blood pressure during the treatment period, with the remaining patient (no. 8) showing a worsening of these parameters (Supplementary Table S2) [36].

 

mRNA expression level of SST2 in corticotroph tumors. SST2 mRNA expression in responder (n = 2), partial responder (n = 1), and nonresponder (n = 1). SST2 mRNA expression level in somatotroph tumors (filled bar) was included for comparison (n = 10; ratio over HPRT, mean ± SEM: 0.27 ± 0.08), as published previously by our group using a similar protocol [32].

Figure 3.

mRNA expression level of SST2 in corticotroph tumors. SST2 mRNA expression in responder (n = 2), partial responder (n = 1), and nonresponder (n = 1). SST2 mRNA expression level in somatotroph tumors (filled bar) was included for comparison (n = 10; ratio over HPRT, mean ± SEM: 0.27 ± 0.08), as published previously by our group using a similar protocol [32].

Abbreviations: HPRT, hypoxanthine phosphoribosyltransferase; non-resp, nonresponder; partial resp, partial responder; pt, patient.

Partial Responders

Among the 4 patients (patients 5, 10, 14, and 16) with a partial response to octreotide monotherapy, UFC levels were sustained for 1 to 2 months in 3 patients with a gradual increase after ketoconazole discontinuation (Fig. 2B). In another patient, UFC levels at follow-up had decreased by at least 50% compared to baseline, albeit still at abnormal levels (Fig. 2B, patient 16). For all 4 patients, the mean UFC at baseline was 2.32 ± 0.33 and 2.18 ± 0.34 times the ULN at follow-up at the end of the study period (P = .83). No significant change in CDR was observed, with a plasma cortisol Pm/am ratio of 0.99 ± 0.14 at baseline compared to 0.94 ± 0.07 at follow-up. Three out of 4 partial responders (patients 5, 14, and 16) showed improvement in weight and waist circumference at follow-up. Blood pressure control improved in 2 patients (no. 14 and 16). In 1 patient (no. 5), blood pressure was normal at baseline and remained unchanged throughout the study period. One partial responder (patient 10) showed worsening of all these clinical parameters (Supplementary Table S2) [36].

Nonresponders

In the nonresponder group, UFC increased in all 4 patients (no. 2, 4, 12, and 15) immediately after ketoconazole discontinuation despite increased doses of octreotide up to 30 mg/month (Fig. 2C). In 3 (patients 2, 4, and 15) out of 4 nonresponders, UFC levels were unchanged during follow-up compared to baseline. In 1 patient (no. 12), the UFC level at follow-up was doubled compared to baseline. The cortisol Pm/am ratio did not improve during treatment (P = .20). Three (patients 2, 4, and 12) of 4 nonresponders lost weight at follow-up. Blood pressure remained unchanged in all 4 patients (Supplementary Table S2) [36].

Ketoconazole-Cabergoline Combination Treatment

Finally, in 2 patients with baseline UFC levels of 2.31 and 1.55 ULN, hypercortisolism could not be controlled with ketoconazole monotherapy. The addition of cabergoline did not result in a normalization of UFC. Patients remained uncontrolled during the study period, and an alternative treatment modality was implemented.

In Vitro Studies

Corticotroph tumor tissue was available for the assessment of SST2 mRNA in 4 patients: 2 responders (patients 8 and 13), 1 partial responder (patient 5), and 1 nonresponder (patient 15) (Fig. 3) who underwent transsphenoidal surgery after the trial. Of these, all but 1 patient had normalized UFC levels before surgery. The nonresponder (patient 15) had slightly elevated UFC (1.22 times the ULN). SST2 mRNA expression was highest in the tissue of the 2 responder patients (patient 8, relative expression 0.803 and patient 13, 0.216 normalized to hprt). It is important to highlight that these SST2 mRNA expression values (0.803 and 0.216) were comparable to SST2 expression in GH-secreting tumors (mean of 0.27 ± 0.30, normalized to hprt, n = 10) as we have previously published [32]. Corticotroph tumor tissue of the partial responder (patient 5) also expressed SST2, albeit at a lower level than the 2 responder patients (0.146 normalized to hprt). SST2 expression was low in corticotroph tumor tissue of the nonresponder (0.08 normalized to hprt).

Paraffin-embedded tissue was available for IHC in 4 patients, of which 1 was a responder (patient 7), 2 were partial responders (patients 5 and 10), and 1 was a nonresponder (patient 15). Both mRNA and protein expression were available and assessed for 2 patients who were a partial responder (patient 5) and a nonresponder (patient 15). Before surgery, UFC levels were slightly elevated in 1 partial responder (patient 10) and the nonresponder (patient 15; UFC 1.17 and 1.22 times the ULN, respectively) but normal in the other patients. The IRS for SST2 was higher in the responder compared to the nonresponder patient (IRS 4 and 0, respectively) (Fig. 4). One partial responder (patient 5) had a high IRS for SST2 (IRS 8) with more than 80% of the adenoma cells staining positive for SST2. The second partial responder (patient 10) had no adenoma cells staining positive for SST2 (IRS 0). This patient had slightly elevated UFC levels prior to surgery (described earlier).

 

Representative immunohistochemistry of SST2 in corticotroph tumors. Representative photomicrographs of SST2 immunohistochemical staining in formalin-fixed paraffin-embedded tissue sections of 4 corticotroph adenomas of patients included in this study. (A) Adenoma patient 7 (responder) (IRS 4); (B) adenoma patient 5 (partial responder) (IRS 8); (C) adenoma patient 10 (partial responder) (IRS 0); (D) adenoma patient 15 (nonresponder) (IRS 0). (E) Positive control SST2 staining in human pancreatic islets. In most corticotroph adenomas, small blood vessels were SST2 positive (see arrows in panel D).

Figure 4.

Representative immunohistochemistry of SST2 in corticotroph tumors. Representative photomicrographs of SST2 immunohistochemical staining in formalin-fixed paraffin-embedded tissue sections of 4 corticotroph adenomas of patients included in this study. (A) Adenoma patient 7 (responder) (IRS 4); (B) adenoma patient 5 (partial responder) (IRS 8); (C) adenoma patient 10 (partial responder) (IRS 0); (D) adenoma patient 15 (nonresponder) (IRS 0). (E) Positive control SST2 staining in human pancreatic islets. In most corticotroph adenomas, small blood vessels were SST2 positive (see arrows in panel D).

Abbreviation: IRS, immunoreactivity scoring system.

Discussion

Selective downregulation of SST2 expression in corticotroph tumor cells by high cortisol levels is thought to impair the efficacy of SST2 preferring somatostatin analogs in the treatment of CD [29, 30]. The transcriptional regulation of SST2 is modulated by glucocorticoids (GC), as it was demonstrated that GC inhibits SST2 promoter activity through GC-responsive elements, resulting in a decrease in SST2 expression [29]. Because this process may be reversible, we examined in a prospective pilot study whether lowering cortisol production with ketoconazole can enhance inhibition of ACTH secretion via subsequent treatment with octreotide in patients with CD. The existing literature of clinical studies using octreotide in CD consisted of case reports (Table 1). This is the first prospective study to evaluate the clinical efficacy of octreotide in CD. Our data may indicate that the sequential strategy treatment with ketoconazole and octreotide can induce sustained biochemical remission in a subset of patients with mild CD.

Several in vivo and in vitro studies provide evidence that SST2 expression in corticotroph tumor cells can recover after suppression of cortisol production or antagonizing cortisol action [27, 33, 38, 39]. As mentioned, we previously demonstrated that SST2 expression is higher in corticotroph tumors of patients operated under controlled cortisol production compared to those of patients with hypercortisolism at the time of operation [32]. However, SST2 expression was only significantly higher at the mRNA level but not at the protein level. Evidence that SST2 expression can also increase at the protein level was provided by case descriptions of 2 patients with ectopic ACTH syndrome [38]. In both patients, the source of ectopic ACTH production was initially occult with negative somatostatin receptor scintigraphy. However, after treatment with mifepristone, antagonizing the effects of cortisol at a tissue level, somatostatin receptor scintigraphy could identify a neuroendocrine lung tumor in both patients, indicating SST2 protein expression. This was recently confirmed by similar observations in 2 patients with an ACTH-producing neuroendocrine lung tumor [39]. In addition, in vitro studies with the selective GC receptor antagonist relacorilant demonstrated the reversal of GC-induced downregulation of SST2 expression in the AtT20 corticotroph tumor cell line [39]. Finally, indirect evidence comes from an older preliminary study in which a further decrease in UFC levels was observed in 4 ketoconazole-treated patients after the addition of octreotide. The ketoconazole dose could subsequently be reduced in 3 patients [27].

The sequential treatment with ketoconazole and octreotide in the present study led to a partial or complete response in 7 out of 11 patients, with 3 of them exhibiting sustained biochemical remission throughout the follow-up period. At the first stage, ketoconazole monotherapy led to normal UFC levels in 79% of the cases. This efficacy is higher compared to previous studies that reported an efficacy of approximately 50% to 60% and can be explained by the fact that the majority of patients had mild hypercortisolism [11, 40-43]. Additionally, the clinical benefit of controlling cortisol secretion was evident with the observed weight loss in most responders to ketoconazole.

Subsequently, the combined therapy (ketoconazole and octreotide) was able to maintain biochemical remission according to UFC levels. No additive effect was observed with add-on treatment during a period of 2 months of combined ketoconazole-octreotide therapy. Following this stage, ketoconazole was stopped, and treatment was continued with octreotide monotherapy that was able to maintain normal UFC levels in 3 (27%) patients. Since the majority of reported cases using octreotide for CD treatment showed failure to induce biochemical remission, as summarized in Table 1, these results suggest that, in a subset of patients, ketoconazole-induced biochemical remission may have indeed led to upregulation of SST2 with subsequent effectiveness of octreotide.

This is supported by the observed dose dependency in the response to octreotide in both the ketoconazole-octreotide combination phase and the octreotide monotherapy phase. In 2 patients treated with ketoconazole and octreotide, UFC levels increased above the ULN after initial normalization but returned to normal values after a dose increase of octreotide. In 2 of the 3 responders to octreotide monotherapy, an increased dose of octreotide was required, and effective, after an initial increase in UFC levels was observed following ketoconazole discontinuation. Of note, given the size of the present study, a starting dose of octreotide cannot be defined based on our data. A previous study showed that ketoconazole can inhibit ACTH secretion in rat corticotroph cells in vitro; therefore, central effects of ketoconazole in vivo cannot be fully excluded [44]. However, sustained normal UFC levels under octreotide monotherapy in 1 responder patient and the dose-dependent response to octreotide in 2 other responders suggest that a central residual effect of ketoconazole is unlikely to explain the response to octreotide.

Interestingly, among the 3 patients considered as responders based on the UFC levels, clinical improvement was observed in 2 patients in terms of weight loss, waist circumference, and blood pressure control. Notably, the small sample size and limited follow-up reduce our ability to assess the long-term clinical impact of the ketoconazole-octreotide sequential strategy.

A common feature of the 3 patients in whom the strategy was most effective is that they had mildly elevated UFC levels at baseline as compared to patients in whom the strategy failed. This is similar to what was observed in studies with another somatostatin analog, pasireotide, which has been shown to be more effective in patients with less severe hypercortisolism [18, 19]. It is important to acknowledge that octreotide has a safer side-effect profile as compared to pasireotide, which is known to induce or worsen hyperglycemia via inhibition of incretin release. Octreotide could, therefore, be a potentially interesting option to maintain remission in (mild) CD after induction therapy with a steroid synthesis inhibitor [31].

When analyzing the 4 nonresponders and 4 partial responders in the trial, in whom, despite ketoconazole effectively reducing cortisol secretion, octreotide monotherapy was unable to maintain normocortisolism, the reasons for a failed response remain speculative. It is possible that because of more severe baseline hypercortisolism in these patients, as compared to the responders, a longer duration of biochemical remission is necessary in order to restore SST2 expression to adequate levels. Alternatively, corticotroph tumors in these cases may not express an adequate amount of SST2, regardless of the cortisolemic state.

Expression of SST2, defined by either immunohistochemical or mRNA level, is positively correlated with octreotide efficacy in GH-secreting tumors [45, 46]. Accordingly, the 2 responder patients to octreotide in whom cortisol levels were normalized before surgery had higher SST2 mRNA expression compared to partial/nonresponder patients, and these SST2 mRNA expression levels were comparable to the levels in somatotroph tumors [32]. The strategy of lowering cortisol levels to increase SST2 expression may have contributed to octreotide efficacy in these patients. Accordingly, an intermediate level of SST2 mRNA was found in the partial responder, whereas the nonresponder patient had a low level of SST2 mRNA. Regarding SST2 protein expression, a responder patient had an intermediate level of SST2, which may explain the efficacy of octreotide treatment. Consistently, the nonresponder patient to octreotide had no SST2 expression as determined by IHC, which may be explained by preoperative hypercortisolism with concomitant effects on SST2 expression level (mRNA and protein). The partial responders had contradictory results, 1 with high and the other with no SST2 expression by IHC. The partial responder with no SST2 protein expression also had high cortisol levels, which may have contributed to this negative result.

The present study needs to be analyzed in light of its inherent limitations. The single-arm design and small sample size, ie, 14 patients with 3 full responders to octreotide, only permits a descriptive analysis without more robust statistics. This is an important limitation, even considering that, given the rarity of CD, the existing literature consists mostly of case reports. Additionally, the period of 9 months of follow-up limited our ability to more thoroughly appreciate the potential clinical benefits associated with the reduction of UFC levels observed with the sequential treatment strategy tested in this trial. The protocol included ACTH measurements every 3 months, so the impact of octreotide treatment on ACTH secretion was not evaluated in the present study. Finally, in corticotroph tumors, only in selected cases sufficient appropriate tissue was available for mRNA and protein analysis. Generally, adenoma tissue pieces in CD are (very) small, representing a challenge to obtaining enough tissue for molecular studies. This is a well-known problem with respect to in vitro studies with corticotroph adenomas.

In conclusion, a treatment strategy consisting of sequential treatment with ketoconazole to lower cortisol levels, followed by octreotide to maintain biochemical remission, may be effective in a subset of patients with mild CD. Additional studies with longer follow-up are warranted to confirm the long-term efficacy of this strategy for the medical treatment of CD.

Funding

The authors received no financial support for this manuscript.

Disclosures

R.A.F. received speakers fees and research grants from Recordati and Corcept.

Data Availability

Some or all datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

Clinical Trial Information

Dutch Trial Register nr. NL37105.078.11.

© The Author(s) 2025. Published by Oxford University Press on behalf of the Endocrine Society.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. See the journal About page for additional terms.

Filed under: Cushing's, Treatments | Tagged: , , , | Leave a comment »

Efficacy and Safety of Pasireotide in Patients With Cushing’s Disease

Posted on April 16, 2025 by MaryO

Abstract

Purpose

Pasireotide is the first pituitary-directed approved therapy for Cushing’s disease (CD), effective in reducing 24 h urine free cortisol (UFC) > 50% in more than half of patients, with beneficial effects and with a relatively high incidence of hyperglycemia. The aim of this study was to evaluate efficacy and safety of long-term treatment with pasireotide (PAS) in CD patients, also according to gender.

Methods

We retrospectively evaluated 19 consecutive CD patients (13F; age at diagnosis: 34.9 ± 11.7 yrs) treated with PAS, referred to and followed-up at the Endocrine Unit of the University Hospital of Messina, from 2013 to 2023. We evaluated and compared, in the whole cohort and after gender stratification, anthropometric, clinical, neuroradiological, hormonal and metabolic parameters, along with CD-related comorbidities, before PAS treatment and at last follow-up visit. Side-effects and adverse events related to treatment were also assessed.

Results

Under PAS treatment: overall, 52.6% of patients achieved a normalization of UFCxULN from baseline without any difference in terms of UFC reduction and/or response to treatment according to gender; two females out of the 19 patients experienced tumor shrinkage. In the whole cohort, at last follow-up visit as compared to baseline: body weight, BMI, total cholesterol, LDL-cholesterol were significantly improved, while HbA1c significantly increased. Prevalence of CD-related comorbidities did not change significantly, while the number of patients with IGF-1 SDS below the sex/age adjusted normal range significantly increased. Stratifying patients by sex, at last follow-up visit vs. baseline, we observed lower total and LDL-cholesterol in men and lower waist circumference in women. Most common adverse events were related to hyperglycemia which led to treatment withdrawal in 3 cases, without any gender difference. Response to PAS correlated with younger age at diagnosis, longer duration of disease, lower Hb1Ac levels and absence of diabetes at baseline. Conclusion: PAS is effective in a significant number of patients with CD, regardless of gender, having a positive impact on lipid profile and on anthropometric parameters. Major adverse events are related to hyperglycemia which is more frequently associated with a worse baseline glycometabolic and lipid profile in both sexes.

 This is a preview of subscription content, log in via an institution  to check access.

Filed under: Cushing's, Treatments | Tagged: , , | Leave a comment »

Insights on Diagnosing and Managing Cushing’s Syndrome

Posted on August 18, 2024 by MaryO

Cushing’s syndrome, or endogenous hypercortisolemia, is a rare condition that both general practice clinicians and endocrinologists should be prepared to diagnose and treat. Including both the pituitary and adrenal forms of the disease, the Endocrine Society estimates that the disorder affects 10 to 15 people per million every year in the United States. It is more common in women and occurs most often in people between the ages of 20 and 50.

Even though Cushing’s remains a rare disease, cortisol recently made waves at the American Diabetes Association 84th Scientific Session. A highlight of the meeting was the initial presentation of data from the CATALYST trial, which assessed the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes (A1c 7.5+).

CATALYST is a prospective, Phase 4 study with two parts. In the prevalence phase, 24% of 1,055 enrolled patients had hypercortisolism, defined as an overnight dexamethasone suppression test (ODST) value greater than 1.8 µg/dL and dexamethasone levels greater than 140 µg/dL. Results of CATALYST’s randomized treatment phase are expected in late 2024.

Elena Christofides, MD, FACE, founder of Endocrinology Associates, Inc., in Columbus, OH, believes the CATALYST results will be a wake-up call for both physicians and patients seeking to advocate for their own health. “This means that nearly 1 in 4 patients with type 2 diabetes have some other underlying hormonal/endocrine dysfunction as the reason for their diabetes, or significant contribution to their diabetes, and they should all be screened,” she said. “All providers need to get comfortable with diagnosing and treating hypercortisolemia, and you need to do it quickly because patients are going to pay attention as well.”

In Dr. Christofides’ experience, patients who suspect they have a hormonal issue may start with their primary care provider or they may self-refer to an endocrinologist. “A lot of Cushing’s patients are getting diagnosed and treated in primary care, which is completely appropriate. But I’ve also met endocrinologists who are uncomfortable diagnosing and managing Cushing’s because it is so rare,” she said. “The important thing is that the physician is comfortable with Cushing’s or is willing to put in the work get comfortable with it.”

According to Dr. Christofides, the widespread popular belief that “adrenal fatigue” is causing millions of Americans to feel sick, tired, and debilitated may be creating barriers to care for people who may actually have Cushing’s. “As physicians, we know that adrenal fatigue doesn’t exist, but we should still be receptive to seeing patients who raise that as a concern,” said Dr. Christofides. “We need to acknowledsalige their lived experience as being very real and it can be any number of diseases causing very real symptoms. If we don’t see these patients, real cases of hypercortisolemia could be left undiagnosed and untreated.”

Dr. Christofides, who also serves as a MedCentral Editor-at-Large, said she reminds colleagues that overnight dexamethasone suppression test (ODST) should always be the first test when you suspect Cushing’s. “While technically a screening test, the ODST can almost be considered diagnostic, depending on how abnormal the result is,” she noted. “But I always recommend that you do the ODST, the ACTH, a.m. cortisol, and the DHEAS levels at the same time because it allows you to differentiate more quickly between pituitary and adrenal problems.”

Dr. Christofides does see a place for 24-hour urine collection and salivary cortisol testing at times when diagnosing and monitoring patients with Cushing’s. “The 24-hour urine is only positive in ACTH-driven Cushing’s, so an abnormal result can help you identify the source, but too many physicians erroneously believe you can’t have Cushing’s if the 24-hour urine is normal,” she explained. “Surgeons tend to want this test before they operate and it’s a good benchmark for resolution of pituitary disease.” She reserves salivary cortisol testing for cases when the patient’s ODST is negative, but she suspects Cushing’s may be either nascent or cyclical.

Surgical resection has long been considered first-line treatment in both the pituitary and adrenal forms of Cushing’s. For example, data shared from Massachusetts General Hospital showed that nearly 90% of patients with microadenomas did not relapse within a 30-year period. A recent study found an overall recurrence rate of about 25% within a 10-year period. When reoperation is necessary, remission is achieved in up to 80% of patients.

As new medications for Cushing’s syndrome have become available, Dr. Christofides said she favors medical intervention prior to surgery. “The best part about medical therapy is you can easily stop it if you’re wrong,” she noted. “I would argue that every patient with confirmed Cushing’s deserves nonsurgical medical management prior to a consideration of surgery to improve their comorbidities and surgical risk management, and give time to have a proper informed consent discussion.”

In general, medications to treat Cushing’s disease rely on either cortisol production blockade or receptor blockade, said Dr. Christofides. Medications that directly limit cortisol production include ketoconazole, osilodrostat (Isturisa), mitotane (Lysodren), levoketoconazole (Recorlev), and metyrapone (Metopirone). Mifepristone (Korlym, Mifeprex) is approved for people with Cushing’s who also have type 2 diabetes to block the effects of cortisol. Mifepristone does not lower the amount of cortisol the body makes but limits its effects. Pasireotide (Signifor) lowers the amount of ACTH from the tumor. Cabergoline is sometimes used off-label in the US for the same purpose.

Following surgery, people with Cushing’s need replacement steroids until their adrenal function resumes, when replacement steroids must be tapered. But Dr. Christofides said she believes that all physicians who prescribe steroids should have a clear understanding of when and how to taper patients off steroids.

“Steroid dosing for therapeutic purposes is cumulative in terms of body exposure and the risk of needing to taper. A single 2-week dose of steroids in a year does not require a taper,” she said. “It’s patients who are getting repeated doses of more than 10 mg of prednisone equivalent per day for 2 or more weeks multiple times per year who are at risk of adrenal failure without tapering.”

Physicians often underestimate how long a safe, comfortable taper can take, per Dr. Christofides. “It takes 6 to 9 months for the adrenals to wake up so if you’re using high-dose steroids more frequently, that will cause the patient to need more steroids more frequently,” she explained. “If you’re treating an illness that responds to steroids and you stop them without tapering, the patient’s disease will flare, and then a month from then to 6 weeks from then you’ll be giving them steroids again, engendering a dependence on steroids by doing so.”

When developing a steroid taper plan for postoperative individuals with Cushing’s (and others), Dr. Christofides suggests basing it on the fact that 5 mg of prednisone or its equivalent is the physiologic dose. “Reduce the dose by 5 mg per month until you get to the last 5 mg, and then you’re going to reduce it by 1 mg monthly until done,” she said. “If a patient has difficulty during that last phase, consider a switch to hydrocortisone because a 1 mg reduction of hydrocortisone at a time may be easier to tolerate.”

Prednisone, hydrocortisone, and the other steroids have different half-lives, so you’ll need to plan accordingly, adds Dr. Christofides. “If you do a slower taper using hydrocortisone, the patient might feel worse than with prednisone unless you prescribe it BID.” She suggests thinking of the daily prednisone equivalent of hydrocortisone as 30 mg to allow for divided dosing, rather than the straight 20 mg/day conversion often used.

What happens after a patient’s Cushing’s has been successfully treated? Cushing’s is a chronic disease, even in remission, Dr. Christofides emphasized. “Once you have achieved remission, my general follow-up is to schedule visits every 6 months to a year with scans and labs, always with the instruction if the patient feels symptomatic, they should come in sooner,” she said.

More on Cushing’s diagnosis and therapies.

https://www.medcentral.com/endocrinology/cushings-syndrome-a-clinical-update

Filed under: adrenal, adrenal crisis, Cushing's, Diagnostic Testing, pituitary, Treatments | Tagged: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment »

Next Page »